20th-century French artist
01. Matisse & Sadko - Promise You (feat. Justin J. Moore) (Extended Mix) 02. Swedish House Mafia - Ray of Solar (Mau P Extended Remix) 03. ID - Dust (Extended Mix) 04. BBE - Seven Days And One Week (BLR Remix) 05. Don Diablo - Let Me Love You 06. Future Anthem: Armin van Buuren feat. Anne Gudrun - Love Is A Drug (Extended Mix) 07. Becky Hill x Chase & Status - Disconnect (Tiësto Remix) 08. Deorro & Dave Mak & Scheffwell - Hands Up (Extended Mix) 09. DJ Aligator x Thoby - Turn Up The Heat (Extended Mix) 10. NWYR Selects: NWYR – Spitfire 11. KEVU - Orion 12. AXMO x nanobii – Euro Fever 13. Josh Dorey - Feed Your Soul (Extended Mix) 14. Showtek & Justin Prime - Cannonball (Dimitri Vegas & Like Mike vs Bassjackers Extended Remix) 15. Vini Vici x Gabry Ponte - Damage (Extended Mix) 16. NERVO x Ben Nicky feat Madlucky - Hey Yesterday 17. Naeleck x Oditty – Kabuki 18. le Shuuk ft. Meryll – High On Life File Download (59:07 min / 81 MB)
On this very artsy edition of Learned Lately, Hallie tells us all about two prominent artists that we haven't yet talked about, whom you may mix up sometimes, Henri Matisse and René Magritte!Theme music: "Thinking it Over" by Lee Rosevere, licensed under CC BY 2.0E-Mail: email@example.com Facebook: https://www.facebook.com/quizandhers/Twitter: https://twitter.com/quizandhersInstagram: https://www.instagram.com/quizandhers/
Vivimos en un mundo que está en constante cambio, y nosotros estamos cambiando junto con él. Nuestro cuerpo cambia, nuestros gustos cambian, los años pasan.Saber cuándo es el momento de hacer cambios en nuestra vida es clave para seguir avanzando.De esto platicamos con Melissa, Pablo y Román, mejor conocidos como Matisse, un grupo musical que la está rompiendo en la industria musical, son los invitados de lujo de este jueves y estoy seguro de que su historia te va a servir de IMPULSO para en los momentos de grandes cambios.Y no te pierdas el estreno de Okay de Matisse Ft Luis Mexia a las 6:00 PM CDMX: https://Matisse.lnk.to/OkayWatchpageColaboraciones y conferencias: firstname.lastname@example.org Hosted on Acast. See acast.com/privacy for more information.
What you'll learn in this episode: How Arnoldsche collaborates with authors to create an effective design for each book What young artists should know before trying to publish a book How Dirk keeps tabs on trends and new developments in jewelry and decorative arts How Arnoldsche selects the right markets and languages for its books Why the art book market has changed dramatically over the last 10 years, and how Arnoldsche has adapted About Dirk Allgaier: Since April 2015, Dirk Allgaier has headed Arnoldsche Art Publishers, an internationally active publisher of art books that offers a unique list of titles in the fields of fine art, applied art and design. With great expertise, sheer hard work and a passion for his profession, he and his team ensure that books from Arnoldsche become what they are: high-quality, individually designed publications and book objects that transport the broad range of creative endeavor in all its diversity across the globe. Additional Resources: Arnoldsche Art Publishing's Website Arnoldsche Art Publisher's Instgram Arnoldsche Art Publisher's X/Twitter Photos Available on TheJewelryJourney.com Transcript: No other publishing house in the world has published as many books on jewelry, ceramics and other applied arts as Arnoldsche Art Publishing. Led by Dirk Allgaier, Arnoldsche is the go-to source for anyone who wants to learn more about the decorative and applied arts, the people who create them, and the museums that exhibit them. Dirk joined the Jewelry Journey Podcast to talk about how he selects the 10 to 15 books Arnoldsche publishes each year; how he works with artists to create a beautiful and informative book; and why a language barrier doesn't always prevent someone from reading an art book. Read the episode transcript here. Sharon: Hello, everyone. Welcome to the Jewelry Journey Podcast. This is the first part of a two-part episode. Please make sure you subscribe so you can hear part two as soon as it's released later this week. My guest is Dirk Allgaier of Arnoldsche Publishing. They're art publishers, and if you have any kind of design library—and that includes jewelry, ceramics, monographs on artists, furniture and more—you no doubt have books that have been published by Arnoldsche. As I was browsing the books online, I kept seeing so many books I have that I didn't know were published by Arnoldsche. For the most part, they are in English and German, and the books are beautifully printed. Dirk will tell us how his path took him to where he is today. Dirk, welcome to the program. Dirk: Thank you very much, Sharon. Very glad to be here. Sharon: I'm so glad to have you here. Dirk was just telling me that he has lived in Stuttgart for 30 years, 25 years, a long time. Can you tell us what a publisher does? Dirk: That's a very good question, Sharon. There's really a lot to it. I tried to explain to you some things, to tell you about some things. Mainly it is my job to see that we put together an attractive book program every six months, every half-year. This is in the field of applied arts, which is our main series of books. It's jewelry, ceramics, textiles, wood and glass, but also the areas of visual design, of the visual arts and design. I receive many book proposals. I have to check them. I have to calculate them, but I've also got to be active by myself from my side, and I have to talk to artists. I have to meet museum curators. For example, I go to museums, to exhibition openings. I go to Schmuck in Munich, so I'm really traveling a lot. I visit all these places. You also have to be in the field where our publishing areas are, in the field of jewelry, of ceramics. I have to be there; I have to be active. In parallel, we have to put out used books. We have 10, 15 books always in parallel production, and we have to approach miniatures. The production is supervised by the project managers, but I'm integrated into the processes of each book because I have to know the exact starters of every book project. I must be approachable by the artist, by the museum curator, by the director if any problem arises or if important decisions have to be made. So, one part is traveling; the other part is production. I'm also responsible for sales and marketing. We have a colleague who does this, but I also have to look at how things can be optimized, how we can sell the books in the best way internationally. Unfortunately, a lot of administrative tasks have to be done. They are also very extensive. Finally, I write some articles for newspapers, for magazines. I give talks. I hold speeches for exhibition openings. I attend meetings, or I'm speaking for podcasts like now. This is also a very interesting and exciting part of my role as a publisher. All in all, there's a lot of work, enough work to work for at least seven days a week. Sharon: Are you saying that right this minute, there are 10 to 15 books that are being worked on? Dirk: Yes, that's it. About 10 to 15 books are always in production parallel, in the different steps of production. Either we are actually starting the editing, or we are preparing the design, or we are doing translations, or we are doing the color separations. Today, the Schmuckmuseum of Pforzheim curator was here. We're doing a new book about jewelry and metalwork, and we checked the colors. We checked the color proofs today. We discussed the cover. There are always a lot of book productions in parallel here at Arnoldsche. Sharon: This is something that is just occurring to me. Do they have input? If they don't like the color, can they say to you they don't like the color? Dirk: That's very important. I try to show everything to my partner, to the museum or to the artist. I show them the design concept of the book so we are not only designing the book. Before we start with the real design, we make some tests on pages, and we send the pages to the artist or to the museum. We say, “Oh, look, the book could look like these pages. Here is a type that's the kind of like the images. The captions are like that. We have some special colors.” Then the museum can say, “Oh, I like it. Please continue,” or “Oh no, I want to have a different kind.” This is very important for me in the production, to work as closely as possible together with the museum or the author. Sharon: Can the museum come and say, “I had something totally different in mind”? Can whoever is working on the book say they had something else in mind? Dirk: Yes, they can say it. Usually, we get a briefing and the museum tells me, “Oh, I want a very modern book,” or “Very conservative,” or “I have some crazy ideas.” But it must fit to the topics; that's very important. We publish books about 18th century arts and crafts, about porcelain from the 18th and 19th centuries. Here's a design that has to be quite conventional, or conservative is a better word. But if we work with a very unusual, contemporary designer, we can be much more provocative and contemporary in the design. Sharon: How did you come to publishing art and applied design books? Do you have a background in it? Dirk: Yes, I'll tell you shortly the story of the company. Arnoldsche, our publishing house, was founded in 1985. This is now almost 40 years ago. The founder of the publishing house—he passed away five years ago—his name was Dieter Zühlsdorff. He had previously, back in the 1970s, lived here in Stuttgart. He had a gallery for fine arts, for paintings, but his real passion was not the fine arts; it was ceramics. In the late 70s, early 80s, he closed the gallery and wrote an encyclopedia of ceramic marks. He traveled throughout Europe. There was no email, no websites. Maybe a fax machine was the most modern technical thing. He traveled for five years and wrote the “Ceramic Marks Encyclopedia” on the Art Nouveau and Art Deco period from 1880 to 1930. When the manuscript was finished, he went in search of a publisher. He didn't plan to found a publishing house, but no publisher wanted to publish his “Ceramic Marks Encyclopedia,” so he was not sure what to do. He sold a painting from his collection to a large bank in Germany. He used this money to print his “Ceramic Marks Encyclopedia,” and that was the beginning of Arnoldsche Art Publishers. That encyclopedia became a best seller in a total of four editions. The name Arnoldsche comes from his wife at the time. She's living. Her name is Gabriela Arnold; Arnold is her last name. Arnoldsche is still a little bit complicated for English speakers. Here, Arnoldsche sounds much better in German than Zühlsdorff, which was the last name of the founder. That's a Pomeranian name, very complicated. I think the English people would not be able to pronounce that name. So, we decided on Arnoldsche, and in German, we say Verlaganstadt. Verlaganstadt means publishing house. That sounds a little bit old-fashioned, but I like that old-fashioned name. In English we say Arnoldsche Art Publishers. Dieter Zühlsdorff, he acted very wisely when he founded the company because he realized there were many publishers in the area of fine arts or architecture, but there was no publishing house that explicitly dealt with the applied arts, with jewelry, ceramics, glass and furniture. So, we can say internationally, Arnoldsche is the only publishing house in the world that focuses on jewelry, ceramics, glass and textile, and we realized a lot of publications in that field. Sharon: Did you have a background in it? Dirk: I'm a trained archaeologist. I'm not an art historian. I studied archaeology. I made my degree. I like it very much, but artistry has fascinated me from a very young age. When I was a child, I went with my parents to see museums, to meet artists. My parents had a collection of paintings. When I completed my studies, I did a separate training course to become a publishing house clerk. This training course lasted one year. It included a three-month internship in a publishing house, and you had to take care of this internship by yourself. I had no idea where to apply. I was in Stuttgart, and I had a friend who was a bookseller. She gave me a recommendation. She told me, “Apply to a small art publishing house here in Stuttgart. They make the most beautiful books, and they are just around the corner from the place where you have the training.” She was speaking about Arnoldsche. So, I went there about 30 years ago, in 1993, and I got the job for a three-month internship at Arnoldsche. It started for three months, and now I'm working for 30 years at Arnoldsche. I'm very grateful to my friend for her recommendation. We still meet regularly even though she now lives in northern Germany. I'm very thankful to her for recommending me. “Go to Arnoldsche, ring the bell and apply for a job.” I did that 30 years ago. Sharon: Wow! Like you said, you must be approached all the time by people who have ideas and say, “Why don't you do a book on this?” or “I have all this material on that.” How do you decide which books to do? Dirk: That's always a difficult decision because we receive a lot of proposals for book productions. For one thing—and I think that's very important—the book has to fit in our program. For example, a book about the photography of the Alps or about Renaissance art would not fit well in our program. For us, it's very important to find new topics; in other words, topics that have not been published before. It makes no sense for us to publish a 50s book about Picasso or about Matisse; that's not our interest. There has to be a market for a book. It has to be saleable. We have to publish books about artists who have worked for many decades in their fields. Also, younger artists come to me. They're in their late 30s or their 40s, and they ask for a book. I often say, “Wait another 10 years. You need a bigger work of art, a mature work, and then you can come back to me and we can think about a book.” Very important art books on the theme of jewelry are the books about the great masters of jewelry. These are really important publications. Just to name a few, for example, Otto Künzli, the Swiss artist, Bernhard Schobinger, Manfred Bischoff. Last year, we published a book about Joyce Scott, the American artist, and the Israeli artist Deganit Stern Schocken, Therese Hilbert. Here, a large body of work over many decades can be wonderfully presented in a beautiful book form. That's really exciting. There are publications on collections of contemporary jewelry. This is also very important. These are mainly museum collections. For example, we have published about the jewelry collection of Eva and Peter Herion in Munich, which you can see when you go down to the basement. It's a major publication about the collection of the jewelry museum in Pforzheim, the Schmuckmuseum. We did it in 1998 with the legendary former director, Fritz Falk. There's the GRASSI Museum in Leipzig, a very important museum in East Germany. There's a very traditional collection and there's a collection of jewelry. They started to collect in the 1920s. We did a book about the jewelry collection of Sylvia Seal and of Art and Design in New York also. These collections are very exciting for us. I do not want to forget to mention the legendary publication by Helen Drutt, “Ornament as Art.” It's about her collection, which is now in the Museum of Fine Arts in Houston. People call that book the “orange book” or the “Bible of jewelry books.” I think you know that book. What's also very important for us are theory books about jewelry. We have a book on the jewelry of Marjan Unger from the Netherlands. She did the book “Jewelry in Context.” These books are very important for students, for example. They are quite affordable in price. They're 15 Euros, so students buy these theory books. If you come to Arnoldsche, there's finally one topic that is very important because it's the most elementary, because every book can't be one: special books. We are publishing in a niche; it's a real niche, and the quantity of books, the editions, are not so high. Every book needs special financial support, so we ask for financial support from foundations. The potential sales is low compared to the very high cost of distribution. You do not usually recoup the high production cost. So, museums, collectors, foundations themselves make books financially possible in the first place through a corresponding purchased quantity. That is how a book can be realized through financial support; by purchasing books in advance. A special part will be paid by Arnoldsche and for the other part, we look for sponsors or our foundations to financially support it. These are the different things to consider for Arnoldsche book publishing. Sharon: When you are out and about—let's say you're traveling—do you find exhibits that you didn't know about or things you can approach people about? Dirk: Yes, I go to exhibition openings. Of course, I go to Schmuck in Munich, a big Schmuck event. I go to Munich, to exhibition openings. I go to Norway, to Switzerland, and I always meet the artists. I also meet authors and they tell me, “Oh, I'm working on a project. I'm working with this artist or with that museum. They are looking for a publisher. Would you mind if I make a contact?” For me, it's very important to visit these places, to go to openings, to meet curators because we are like a big family. Everybody knows something and people speak with each other. They say, “Here's a project. There is a book. It's planned to be an exhibition. They are looking for a publisher. They are planning a book for next year,” and I say, “O.K., please, if you can make a connection and the person can contact me.” Then we are discussing the possibility of collaboration for the book project. Sharon: Do they come with photographs or do you say, “I want to photograph this”? Dirk: For me, it's important to have an exposé, a short summary of the book. What is in the book, what is the sense of the book, whom do I want to reach with the book, who is the audience? And to send me some photographs, some preliminary information to get an idea of how the book will be, what the topic of the book is. That's enough for me, and then we continue our discussion. Sharon: Do you or your production assistants decide the cover of the book and what it will look like? Who decides? Dirk: We have freelance designers. We work together, but often artists or jewelers or ceramic artists who are planning a monograph about their work, they bring their own graphic designers with them. That's often fine with me because the collaboration between artist and designer is very intensive, and artists and designers should work together personally as often as possible. Often at Arnoldsche, we are responsible for the design, but always in collaboration with the artist. We have a graphic designer. We've worked together with her for almost 13 years. She designs many of our books and many artists know her. They come to us. They say, “We're planning a book, but we want to have this designer. We trust this designer.” There are artists who give us the whole material. They give us the photographs and the text, then they make a book and she makes a design. We show it before printing and they say, “Oh, make this little change. Oh, make that little change. Go to the press.” There are other artists who look very carefully, who ask for changes, but every one is absolutely fine for us. We love to work together with her. She designed the book on Helen Drutt for “Ornament as Art,” the orange book, but she also designed important jewelry monographs; for example, the book on Sam Kramer, a jewelry designer. She did the book about Giampaolo Babetto, about Fritz Maierhofer from Austria, about Georg Dobler or Claus Bury, two famous German designers. Usually, we say if a graphic designer designs the inside pages of a book, they also have to design the cover. The inside pages and cover have to be in accordance with each other. It should fit to each other. That's very important, to have one designer for the whole book. A designer is also like an artist in a way. You cannot ask an artist to make this part and another artist makes this part. The whole book has to be in the hands of one designer. Sharon: We will have photos posted on the website. Please head to TheJewelryJourney.com to check them out.
The Martin Garrix Show #471Tracklist - http://1001.tl/k2lfcmMix 11. Lufthaus - Sunlight (Extended Mix) [Armada Music]2. Citadelle - Pilot (Feel Tonight) (Extended Mix) [STMPD RCRDS]3. Zakes Bantwini, Kasango - Osama (Claptone Remix) (Extended Mix) [UMG]4. ID - ID [STMPD RCRDS]5. VOLAC - Come Back [MIRAGE MUSIC]6. Mason Collective X Bipolar Sunshine - People In Love (Extended Mix) [DEFECTED]7. Jewel Kid - Nobody Move [TOOLROOM]8. Beyond Chicago X Majestic X Alex Mills - Million Dollar Bill (Majestic Extended VIP) [D4D4NCE]9. BBE - Seven Days And One Week (BLR Remix) [WHITE LABEL] Mix 2 10. Matroda, TOBEHONEST - Talk To Me [TERMINAL UNDERGROUND]11. Chris Lake, Aluna - More Baby (Extended Mix) [Black Book/Astralwerks]12. Bob Sinclar x A-Trak x Melé - Deep Inside Of Me [DEFECTED]13. Moksi, Eleganto - Black on Black [BARONG FAMILY]14. Mikey Barreneche & Forti - Check This [STMPD RCRDS]15. Madison Mars x NIGHT/MOVES - Kickback [HEXAGON]16. The Weeknd - Can't Feel My Face (Martin Garrix Remix) [UMG]17. Blinders - Howling [STMPD RCRDS]18. Matisse & Sadko & James French - Pull Me Through The Fire [STMPD RCRDS]A weekly selection of tracks that I love to listen to at home or play out at a party. New episodes uploaded weekly.
Stéphane Bern raconte un peintre aux nombreux chefs d'œuvres et au style parfaitement reconnaissable, qui a chamboulé les codes de la peinture avant d'élire domicile sur la Riviera. Ou la véritable histoire de Henri Matisse à Nice. Pourquoi a-t-il choisi de s'installer à Nice ? Peut-on poser un chevalet sur des galets ? Comment cette ville du sud a pu inspirer son art, notamment à la fin de sa vie ?Pour en parler, Stéphane Bern reçoit l'historienne de l'art Claudine Grammont, commissaire de l'exposition “Matisse années 1930. À travers Cahiers d'Art” au musée Matisse à Nice et directrice de l'ouvrage 'Tout Matisse' (Robert Laffont/Bouquins)
01. re:run - The Unknown [TOOLROOM] 02. Tom & Collins, Andruss - Morena [ANOTHER RHYTHM] 03. Wuki - Sunshine (My Girl) [THRIVE] 04. Eleganto - Drop It [STMPD RCRDS] 05. YTRAM & Citadelle - Alive [STMPD RCRDS] 06. Martin Garrix & Dallas K & Sasha Alex Sloan - Loop [ASTRALWERKS/STMPD] 07. Funkin Matt - Firmament [HELDEEP] 08. Eli Brown - Diamonds On My Mind (Clean) [UMG] 09. Dillon Francis, Alesso, Clementine Douglas - Free [ASTRALWERKS] 10. Crime Zcene - Wild [STMPD RCRDS] 11. Don Diablo & RetroVision - Set Me Free [HEXAGON] 12. MAKJ x Luis Torres - PSA [MUSICAL FREEDOM] 13. Mike Williams & Tim Hox - The Blond One (Wanna Party) [SPINNIN] 14. HUTS, Louis III - Brand New (Lucles Remix) [HMG] 15. Cheyenne Giles - Run It All Night [SPINNIN] 16. Martin Garrix & Brooks - Quantum [STMPD RCRDS] 17. Matisse & Sadko - Promise You feat. Justin J Moore [TOMORROWLAND MUSIC] 18. Martin Garrix feat. JRM - These Are The Times [SONY/STMPD]
Guest mix by Varsetti 01. Eran Hersh & Anorre - Regained (Extended Mix) [HELDEEP] 02. Bigfett - Signals (Extended Mix) [KONTOR] 03. Sevenn & Silver Panda - Deep Space (Extended Mix) [PANDA LAB] 04. JES - Forever Young (Morgin Madison Remix) [BLACK HOLE] 05. Kevin de Vries, Mau P - Metro (Extended Mix) [AFTERLIFE] 06. Caroline Lavelle - Could You Run Away (Costa Extended Remix) [RNM] 07. Matisse & Sadko - Promise You (feat. Justin J. Moore) (Extended Mix) [TOMORROWLAND MUSIC] 08. Ruddek, Ventura & Summ - Together (Extended Mix) [VYO] 09. Alok, Ava Max - Car Keys (Ayla) (Tiesto Extended Remix) [B1] 10. KAAZE - La La Life (BLK RSE Extended Remix) [BLK RSE] 11. Paul Kold - Forever Young (Extended Mix) [ARMIND] 12. Paul van Dyk & Sean & Dee - Fragmentation (Extended Mix) [VANDIT] 13. Key4050 & Plumb - I love You (AV Extended Remix) 14. Norni - Papillon (Extended Mix) [COLDHARBOUR] 15. Goom Gum - Set & Setting [TRUESOUL] 16. Gaia - Tuvan (Motion Sound Mash Up) 17. Parnassvs - Daydream (Extended Mix) [PARNASSVS] 18. Robbie Seed - Komorebi (Extended Mix) [FIND YOUR HARMONY] 19. SMR LVE feat. Sue McLaren - Every Breath I Take (Extended Mix) [NOCTURNAL KNIGHTS MUSIC] 20. Anyma & Chris Avantgarde - Consciousness (Greg Downey Remix) [FREE] 21. Solarstone - Vision (Original Mix) [BLACK HOLE] 22. Emma Hewitt x Roman Messer - Fallen (Extended Mix) [BLACK HOLE] 23. Sneijder - Dawn (Extended Mix) [PURE TRANCE NEON] 24. Yoshi & Razner with Cari - Running Over The Rainbow (Extended Mix) [FSOE] 25. Aly & Fila & Alex M.O.R.P.H. feat. Cheryl Barnes - Eye Of The Storm (Extended Mix) [FSOE] 26. Peggy Gou, Maddix - (It Goes Like) Nanana (Maddix Remix) [FREE] 27. DJ's United - Remember Love [ARMADA] 28. Armin van Buuren - Communication (Part 3) [ARMADA] 29. DJ Tiësto - Elements Of Life (Original Mix) [BLACK HOLE]
The Martin Garrix Show #469Tracklist - http://1001.tl/k2lfcmMix 11. re:run - The Unknown [TOOLROOM]2. Tom & Collins, Andruss - Morena [ANOTHER RHYTHM]3. Wuki - Sunshine (My Girl) [THRIVE]4. Eleganto - Drop It [STMPD RCRDS]5. YTRAM & Citadelle - Alive [STMPD RCRDS]6. Martin Garrix & Dallas K & Sasha Alex Sloan - Loop [ASTRALWERKS/STMPD]7. Funkin Matt - Firmament [HELDEEP]8. Eli Brown - Diamonds On My Mind (Clean) [UMG] Mix 29. Dillon Francis, Alesso, Clementine Douglas - Free [ASTRALWERKS]10. Crime Zcene - Wild [STMPD RCRDS]11. Don Diablo & RetroVision - Set Me Free [HEXAGON]12. MAKJ x Luis Torres - PSA [MUSICAL FREEDOM]13. Mike Williams & Tim Hox - The Blond One (Wanna Party) [SPINNIN]14. HUTS, Louis III - Brand New (Lucles Remix) [HMG]15. Cheyenne Giles - Run It All Night [SPINNIN]16. Martin Garrix & Brooks - Quantum [STMPD RCRDS]17. Matisse & Sadko - Promise You feat. Justin J Moore [TOMORROWLAND MUSIC]18. Martin Garrix feat. JRM - These Are The Times [SONY/STMPD]A weekly selection of tracks that I love to listen to at home or play out at a party. New episodes uploaded weekly.
Local Hip-Hop legend Jaeda Templeton stops by the pod to talk to ExZac and Matisse about what inspires her and what we all think the scene is sorely missing. She also talks about her time traveling the world hitch-hiking and riding chicken busses through Mexico. The gang plays a new game in honor of Hip-Hops 50th anniversary. Get Happy! --- Send in a voice message: https://podcasters.spotify.com/pod/show/happy2bherepod/message
Rus Pop MuZiK @ DJ Глюк 1. Baur Karbon - Бесконечность 2. Kali - Смотрю на Тебя 3. DJ Romeo & Matisse feat. Yana Fortep - Закрой Глаза (2023 Edit) 4. DJ SHMELYOV feat. Serzh - Тутитам 5. Misha Levkin - Танцы Под Луной 6. Vadee - Без Тебя 7. SAFIN - Мотылёк 8. GULYAEV - Сирень 9. Яморе - Дом 10. BAGARDI - Mafia 11. Maro feat. What's Up? - Пьяное Такси 12. TUMANOVA feat. ARaveN & KAN - Улетай 13. Bukatara - Влюблена 14. KALI - Не Терпится 15. Канги - Для Тебя 16. Xolidayboy - Тюлени 17. Макс Саян feat. Volfworks - Искра 18. Jaman T - Залечи 19. Tanel - Парашюты 20. Олег Майами - Мельница 21. Dante - Неважно 22. Yacci feat. Genzel - Танцуй 23. Diana Shadi - Подойди Поближе
01. Gui Boratto - Pilgrim [TOMORROWLAND MUSIC] 02. Sony Fodera & MK - Asking feat. Clementine Douglas (Joshwa Remix) [SOLOTOKO] 03. EC Twins - All I Never Need [OH2 RECORDS] 04. Schillist & MEDUN - Back To Love [STMPD RCRDS] 05. San Pacho - Soundboy (Extended Mix) [SINK OR SWIM] 06. Tom & Jame - Into Your Arms (Extended Mix) [BE YOURSELF] 07. Nora van Elken - Harder, Better, Faster, Stronger (Extended Mix) [ETERNAL NIGHTS] 08. Junior Jack - Thrill Me (LO'99 Extended Remix) [ADESSO MUSIC] 09. Kungs & Shadow Child - Changes [VAL] 10. Baauer -
Подкаст «Top Club Chart» выходит каждый понедельник. Подпишись на нас в Apple Podcasts, Castbox и Google Podcasts, чтобы не пропустить новые эпизоды. Комментарии, вопросы и пожелания отправляй на email@example.com Ведущий и продюсер: Тимур Бодров Саундпродюсер: Ярослав Чернобров Редактор подкаста: Дарья Бельдий 1. MEDUZA ft. Sam Tompkins & Em Beihold - Phone (25 место) 2. Murphy's Law - Ain't No Other Man (Rework) (24 место) 3. Harry Romero ft. Leo Wood - Fool For Love (Chris Lake Edit) (23 место) 4. Rezone & MACROLEV - El Ritmo (22 место) 5. Alex Wann - Milkshake (21 место) 6. FISHER & Aatig - Take It Off (20 место) 7. ARTBAT & Another Life - Breathe In (19 место) 8. Gabry Ponte & Don Diablo - Sunglasses At Night (18 место) 9. Matisse & Sadko, Swedish Red Elephant - Holiday (РЕЗИДЕНЦИЯ) 10. Swedish House Mafia - Ray Of Solar (17 место) 11. Alexander Popov & LTN pres. Ghostbeat - Magic Garden (16 место) 12. Pryda - The Return (15 место) 13. MK & Sonny Fodera ft. Clementine Douglas - Asking (14 место) 14. James Mac & Vall ft. Rosalie - The Boy Is Mine (13 место) 15. FISHER ft. Kita Alexander - Atmosphere (12 место) 16. BYOR & Shift K3Y - Whistle (11 место) 17. London Grammar X CamelPhat - Higher (10 место) 18. deadmau5 & Kaskade ft. Haley Gibby - I Remember (John Summit Remix) (9 место) 19. Major Lazer & James Hype - Number 1 (8 место) 20. Steve Angello & Wh0 - What You Need (7 место) 21. Joel Corry & Icona Pop & Rain Radio - Desire (6 место) 22. Madonna - What It Feels Like for a Girl (Above & Beyond Club Mix) (ХИТ ВСЕХ ВРЕМЁН) 23. Jain - Makeba (Ian Asher Remix) (5 место) 24. Mau P & Kevin de Vries - Metro (4 место) 25. Skrillex & Boys Noize - Fine Day Anthem (3 место) 26. Calvin Harris & Sam Smith - Desire (2 место) 27. Fred again.. - adore u (ПЕРСПЕКТИВА) 28. Peggy Gou - (It Goes Like) Nanana (1 место)
The Martin Garrix Show #467Tracklist - http://1001.tl/k2lfcmMix 11. Gui Boratto - Pilgrim [TOMORROWLAND MUSIC]2. Sony Fodera & MK - Asking feat. Clementine Douglas (Joshwa Remix) [SOLOTOKO]3. EC Twins - All I Never Need [OH2 RECORDS]4. Schillist & MEDUN - Back To Love [STMPD RCRDS]5. San Pacho - Soundboy (Extended Mix) [SINK OR SWIM]6. Tom & Jame - Into Your Arms (Extended Mix) [BE YOURSELF]7. Nora van Elken - Harder, Better, Faster, Stronger (Extended Mix) [ETERNAL NIGHTS] 8. Junior Jack - Thrill Me (LO'99 Extended Remix) [ADESSO MUSIC]9. Kungs & Shadow Child - Changes [VAL] Mix 210. Baauer -
01. Jess Glynne - What Do You Do (MK Remix) [EMI] 02. Saffron Stone - Wishing Well [THREE SIX ZERO] 03. Biscits - Do You Feel It [WRONG] 04. BLR - Turn It Around Baby [SPINNIN DEEP] 05. Florian Picasso - Work It [STMPD RCRDS] 06. Wankelmut - Miss Me To Death (Club Mix) [MENTALO] 07. Ferreck Dawn & Mila Falls - On & On [TOMORROWLAND MUSIC] 08. Leandro Da Silva & AtcG - The Master [ARMADA MUSIC] 09. Dopamine & Sigala - Feel It Deep Inside [ATLANTIC] 10. FISHER feat. Kita Alexander - Atmosphere [CATCH & RELEASE] 11. 070 Shake - Cocoon (Martin Garrix & Space Ducks Remix) [UMG] 12. DubVision feat. Nu-La - The Horizon (With You) [STMPD RCRDS] 13. Martin Garrix & Justin Mylo - Burn Out feat. Dewain Withmore [SONY/STMPD] 14. Tujamo x Sick Individuals - Lose Control [SPINNIN] 15. ARTY - Waiting For A Night [ARMADA] 16. Seth Hills - Eclipse [STMPD RCRDS] 17. Matisse & Sadko - Lefka [STMPD RCRDS/TOMORROWLAND MUSIC] 18. Martin Garrix - If We'll Ever Be Remembered feat. Shaun Farrugia [STMPD RCRDS]
The Martin Garrix Show #466Tracklist - http://1001.tl/k2lfcmMix 11. Jess Glynne - What Do You Do (MK Remix) [EMI]2. Saffron Stone - Wishing Well [THREE SIX ZERO]3. Biscits - Do You Feel It [WRONG]4. BLR - Turn It Around Baby [SPINNIN DEEP]5. Florian Picasso - Work It [STMPD RCRDS]6. Wankelmut - Miss Me To Death (Club Mix) [MENTALO]7. Ferreck Dawn & Mila Falls - On & On [TOMORROWLAND MUSIC]8. Leandro Da Silva & AtcG - The Master [ARMADA MUSIC]9. Dopamine & Sigala - Feel It Deep Inside [ATLANTIC] Mix 210. FISHER feat. Kita Alexander - Atmosphere [CATCH & RELEASE]11. 070 Shake - Cocoon (Martin Garrix & Space Ducks Remix) [UMG]12. DubVision feat. Nu-La - The Horizon (With You) [STMPD RCRDS]13. Martin Garrix & Justin Mylo - Burn Out feat. Dewain Withmore [SONY/STMPD]14. Tujamo x Sick Individuals - Lose Control [SPINNIN]15. ARTY - Waiting For A Night [ARMADA]16. Seth Hills - Eclipse [STMPD RCRDS]17. Matisse & Sadko - Lefka [STMPD RCRDS/TOMORROWLAND MUSIC]18. Martin Garrix - If We'll Ever Be Remembered feat. Shaun Farrugia [STMPD RCRDS]A weekly selection of tracks that I love to listen to at home or play out at a party. New episodes uploaded weekly.
1: NARCISS - Love 4 Life2: DYRO – My Way3: SIM0NE – Star Sign4: SHOUSE - YOUR LOVE feat. House Gospel Choir5: ALMERO & PAUL GREEN - Under My Body (Extended Mix)6: MASS MEDIUM - Mindblower (Klubbheads Extended Remix)7: LAR, NU-LA - Erase LISTENERS' CHOICE8: SUNSET BROTHERS - Ibiza Sunrise 9: MATISSE & SADKO – Lefka10: MARTIN SOLVEIG - Now or Never ft. Faouzia (D.O.D Remix)11: FREEJAK - Sol d'en Serra12: ODD MOB - Blisters On My Feet (feat. Basura Boyz) [Extended Mix] TRIED & TESTED13: ROMY – The Sea 14: YOLANDA BE COOL - Segunda (feat. Jonjon) (Extended Mix)15: FRIEND WITHIN - Peanut Squash (Extended Mix)16: TOBTOK & FARFETCH'D – So Good GUEST SELECTION: BIIANCO UNDERWORLD, Dark And Long (Dark Train)BIIANCO - This Beat Is Gonna Eat Me Alive THE WARM UP SELECTION 17: GABRY PONTE X DON DIABLO – Sunglasses At Night 18: SALVATORE GANCI - Your Mother19: FRANKY WAH – Are You Down20: LONDON GRAMMAR x CAMELPHAT - Higher THE MAINSTAGE MIX 21: LP GIOBBI FT. SOFI TUKKER - If Love Is A Skill (Anden Remix)22: OLING - Gershwin23: CIARA - 1, 2 Step (DJ Heartstring Edit)24: BILLY GILLIES FEAT. HANNAH BOLEYN - Billy Gillies feat. Hannah Boleyn25: TRANCE WAX – Love Me Higher26: PAUL VAN DYK & CIARAN MCAULEY - Someone Like You27: DANIEL WANROOY & AK – Summer Sound28: PEGASSI - Wat Is Die Mo
durée : 00:09:41 - L'Invité(e) des Matins d'été - par : Quentin Lafay - Ce sont deux expositions parallèles que propose cette année le musée Matisse de Nice. L'une, “Matisse années 1930. À travers Cahiers d'art”, organisée avec le musée de l'Orangerie à Paris et le Philadelphia Museum of Art ; et l'autre, intitulée “1953-2023 Histoire d'une Collection”. - invités : Aymeric Jeudy Directeur par intérim du Musée Matisse de Nice
durée : 02:02:25 - Les Matins d'été - par : Quentin Lafay - - invités : Mathilde Velliet Chercheuse à l'Université Paris-Cité et au programme de géopolitique des technologies de l'Institut français des relations internationales (IFRI); Emmanuel Hache Economiste à l'IFP EN (Energies Renouvelables), directeur de recherche à l'IRIS, spécialiste de l'Asie du Sud-Est
01. Martin Garrix & Third ≡ Party - Flashlights (Intro Edit) [Stmpd] w/ Nico & Vinz - Am I Wrong (Acappella) [Warner Bros.] 02. Brooks & Vluarr - Id [Stmpd] w/ David Guetta & Martin Garrix & Brooks - Like I Do (Acappella) [Parlophone] 03. Martin Garrix & Moti feat. Jenny Wahlström - Virus (How About Now) [Spinnin'] 04. Tiësto & The Chainsmokers - Split (Only U) (Cheyenne Giles Festival Flip) [Free/Musical Freedom] 05. Martin Garrix & Dubvision - Warriors [Stmpd] w/ Martin Garrix feat. Khalid - Ocean (Acappella) [Epic Amsterdam/Stmpd] 06. Sebastian Ingrosso & Alesso & Ryan Tedder vs. Martin Garrix & Dua Lipa - Calling vs. Scared To Be Lonely (Martin Garrix Mashup) [Refune/Stmpd] w/ Martin Garrix & Mesto vs. Dua Lipa - Limitless vs. Scared To Be Lonely (Martin Garrix Mashup) [Stmpd] 07. Ill Phill & Mesto vs. Sikdope - Seven Nation Snakes (Martin Garrix Mashup) [Fly Eye/Free] 08. Martin Garrix & Blinders vs. Bebe Rexha - Aurora vs. In The Name Of Love (Martin Garrix Mashup) [Stmpd] 09. Martin Garrix X Jvke - Hero (Dubvision Remix) [Stmpd/Epic Amsterdam] w/ Jamie Lewis feat. Michael Watford - For You (Put Your Hands Up In The Air Acappella) [Purple Music] 10. The Weeknd - Can't Feel My Face (Martin Garrix Remix) [Xo] 11. Dubvision - Id [Stmpd] w/ Sander Van Doorn & Martin Garrix & Dvbbs feat. Aleesia - Gold Skies (Acappella) [Spinnin'] 12. Id - Id w/ Martin Garrix feat. Usher - Don't Look Down (Acappella) [Spinnin'/Rca] 13. Lewis Capaldi - Someone You Loved (Martin Garrix Remix) [Virgin] 14. Martin Garrix & Mesto - Chase Me [Stmpd] w/ Tiësto - Lethal Industry [Magik Muzik] w/ Martin Garrix feat. John Martin - Higher Ground (Acappella) [Epic Amsterdam/Stmpd] 15. Id - Id w/ Martin Garrix feat. John Martin - Higher Ground (Acappella) [Epic Amsterdam/Stmpd] 16. Martin Garrix - Animals [Stmpd] w/ Martin Garrix & Blinders feat. Ilsey Juber - Breach (Walk Alone) [Epic Amsterdam/Stmpd] 17. Id - Id w/ Ivan Gough & Feenixpawl feat. Georgi Kay - In My Mind (Acappella) [Axtone] 18. Julian Jordan & Eleganto - Id [Stmpd] 19. Id - Id w/ Avicii feat. Sandro Cavazza - Without You (Acappella) [Umg] 20. Dimitri Vangelis & Wyman - Id w/ Martin Garrix & Matisse & Sadko feat. Pete Wilde - Break Through The Silence (Acappella) [Spinnin'] 21. Martin Garrix & Zedd feat. Emily Warren - Follow [Stmpd] 22. Martin Garrix & Dubvision vs. Avicii & Simon Aldred - Starlight vs. Waiting For Love (D4Ve Mashup) 23. Dimitri Vegas & Like Mike & Martin Garrix - Tremor (Sensation 2014 Anthem) [Spinnin'] 24. Martin Garrix feat. Bonn - High On Life [Epic Amsterdam/Stmpd] 25. Martin Garrix & Sentinel feat. Bonn - Hurricane (Outro Edit) [Stmpd/Tomorrowland Music]
1: BAG RAIDERS - Love Me Back2: SIM0NE – Star Sign3: ARMAND VAN HELDEN - I Won't Stop (Extended Mix)4: RITON X BELTERS ONLY FT. ENISA - Never Knew Love (Extended Mix)5: YOLANDA BE COOL - Segunda (feat. Jonjon) (Extended Mix)6: SWIMMING PAUL – Say Something7: DISCO DOM - Be The One (ft. Yung Bae) LISTENERS' CHOICE8: LUCID - I CANT HELP MYSELF Judge Jules REMIX 9: EWAN MCVICAR – Groove Thang 10: SAM GIRLING - Never On My Own (Extended Mix)11: FREEJAK - Sol d'en Serra (Extended Mix)12: GLIMJI - Phantom SP (Feat. Bisouxx) TRIED & TESTED13: TOBTOK & FARFETCH'D - So Good (Club Mix) 14: MATISSE & SADKO – Lefka 15: LAU.RA - Satisfied (Extended)16: MONA YIM & MEMPHIS LK - Thinkin Of U GUEST SELECTION: VANILLA ACE VenusFickry, Andres Power – Voyage THE WARM UP SELECTION 17: LONDON TOPAZ - All I Need (Aeroplane Remix)18: CRI - I Can Make It [Anjunadeep]19: MARASI – Tormenta (Extended Mix)20: DAVID GUETTA & MORTEN - Something To Hold On To (Extended) THE MAINSTAGE MIX 21: SALVATORE GANACCI - Your Mother (Extended Mix)22: GABRY PONTE X DON DIABLO - Sunglasses at Night (Extended Mix)23: TIËSTO - Drifting (Extended Mix)24: TRANCE WAX - Love Me Higher (Extended Mix)25: PEGASSI - Wat Is Die Mo (Extended Mix)26: AMY WILES - Sweet Feeling (Extended Mix)27: LONDON GRAMMAR X CAMELPHAT - Higher28: THE NOBLE SIX - The Color Out Of Space (J Shorter Version)
01. Martin Garrix & Third ≡ Party - Flashlights (Intro Edit) [STMPD] w/ Nico & Vinz - Am I Wrong (Acappella) [WARNER BROS.] 02. Brooks & GRX - ID [STMPD] w/ David Guetta & Martin Garrix & Brooks - Like I Do (Acappella) [PARLOPHONE] 03. ID - ID w/ Martin Garrix & Matisse & Sadko ft. Pete Wilde - Break Through The Silence (Acappella) [SPINNIN'] 04. DubVision - Spring [STMPD] w/ Jamie Lewis ft. Michael Watford - For You (Put Your Hands Up In The Air Acappella) [PURPLE MUSIC] 05. Martin Garrix & Zedd ft. Emily Warren - Follow [STMPD] 06. Tiësto & The Chainsmokers - Split (Only U) (Cheyenne Giles Festival Flip) [FREE/MUSICAL FREEDOM] 07. Sebastian Ingrosso & Alesso & Ryan Tedder vs. Martin Garrix & Dua Lipa - Calling vs. Scared To Be Lonely (Martin Garrix Mashup) w/ Martin Garrix & Mesto vs. Dua Lipa - Limitless vs. Scared To Be Lonely (Martin Garrix Mashup) [STMPD] 08. Martin Garrix & MOTi ft. Jenny Wahlström - Virus (How About Now) [SPINNIN'] 09. TV Noise - ID [STMPD] w/ Ivan Gough & Feenixpawl ft. Georgi Kay - In My Mind (Acappella) [AXTONE] 10. Martin Garrix - Animals [STMPD] w/ Martin Garrix & Blinders ft. Ilsey Juber - Breach (Walk Alone) [EPIC AMSTERDAM/STMPD] 11. Julian Jordan - ID [STMPD] 12. Ill Phill & Mesto vs. Sikdope - Seven Nation Snakes (Martin Garrix Mashup) [FLY EYE/FREE] 13. Martin Garrix & Blinders vs. Bebe Rexha - Aurora vs. In The Name Of Love (Martin Garrix Mashup) [STMPD] 14. Martin Garrix X JVKE - Hero (DubVision Remix) [STMPD/EPIC AMSTERDAM] 15. ID - ID w/ Sander van Doorn & Martin Garrix & DVBBS ft. Aleesia - Gold Skies (Acappella) [SPINNIN'] 16. The Weeknd - Can't Feel My Face (Martin Garrix Remix) [XO] 17. MAKJ ft. Maria Cardona - Worship [SPINNIN'] w/ Nari & Milani - Atom (Blast Beat GO Acappella) [SIZE] 18. Bingo Players - Devotion [SNEAKERZ] w/ Julian Jordan & Martin Garrix ft. Tinie Tempah - Diamonds [STMPD] 19. Martin Garrix & Breathe Carolina - Something [STMPD/TOMORROWLAND MUSIC] 20. Avicii ft. Simon Aldred - Waiting For Love [PRMD] w/ Martin Garrix vs. Dimitri Vegas & Like Mike vs. Avicii ft. Simon Aldred - Tremor vs. Waiting For Love (Martin Garrix Mashup) [SPINNIN'/PRMD] 21. Avicii ft. Aloe Blacc - SOS (Lucas & Steve Remix) [UMG] w/ Martin Garrix & Brooks - Quantum [STMPD] 22. Martin Garrix & DubVision ft. Shaun Farrugia - Starlight (Keep Me Afloat) [STMPD] 23. Lewis Capaldi - Someone You Loved (Martin Garrix Remix) [VIRGIN] 24. Martin Garrix & Mesto - Chase Me [STMPD] w/ Tiësto - Lethal Industry [MAGIK MUZIK] w/ Martin Garrix ft. John Martin - Higher Ground (Acappella) [EPIC AMSTERDAM/STMPD] 25. Martin Garrix vs. John Martin - Higher Ground vs. Forbidden Voices (Martin Garrix Mashup) [SPINNIN'/EPIC AMSTERDAM] 26. Martin Garrix ft. Bonn - High On Life [EPIC AMSTERDAM/STMPD] 27. Martin Garrix & Sentinel ft. Bonn - Hurricane (Outro Edit) [STMPD/TOMORROWLAND MUSIC]
FEEL 30 Min Melodic Mix 01. Max Brhon - Humanity [FREE] 02. NoMosk - In My Head (Extended Mix) [SUANDA DANCE] 03. LAR & Nu-La - Erase (Extended Mix) [ZEROTHREE] 04. Dirkie Coetzee presents Deeper Calling - Dream Machine (Original Mix) [WE ARE TRANCE DEEP] 05. London Grammar & CamelPhat - Higher (Extended Mix) [MOS] 06. Teklix - Mantric Fusion (Extended Mix) [OUTTA LIMITS] 07. Nicholas Gunn feat. 88Birds - Heart of Gold (Extended Mix) [BLUE DOT MUSIC] 08. FEEL - Kylie (Extended Mix) [SOAVE] 09. KREAM & Coco Star - I Need A Miracle (Extended Mix) [MUSICAL FREEDOM] 10. Matisse & Sadko - Lefka (Extended Mix) [STMPD] Roman Messer 30 Min Guest Mix 11. Roman Messer & Mike Zaloxx with Jennifer Rene - Lately (Airborn Remix) [SUANDA] 12. Armin van Buuren & Arkham Knights vs. Alex M.O.R.P.H. vs. Roman Messer & Cari - Communication vs. Running For Peace vs. Serenity (Armin van Buuren Mashup) [VANDIT / ARMADA / SUANDA] 13. Roman Messer ft. Roxanne Emery - Lost & Found (Full Fire Mix) [SUANDA] 14. Roman Messer - Coming Home [SUANDA DANCE] 15. Roman Messer & Alex M.O.R.P.H. - CYBERIA [SUANDA] 16. Roman Messer & Richard Bedford - Breathe (Alex M.O.R.P.H. Remix) [SUANDA] 17. Roman Messer & Somnia - The Edge [SUANDA] 18. Roman Messer & Airwalk3r - I Turn To You [Future Sequence] Papulin 30 Min Guest Mix 19. Papulin & Dj Eldorados - My Americano Is Not For You (Extended Mix) 20. Chris Schweizer - My Mind (Extended Mix) [ASOT] 21. Davey Asprey - Revolution (Extended Mix) [ASOT] 22. Harmonic Wave - Never Lose Heart (Extended Mix) [Invironment (Abora Music Group)] 23. ThoBa & Kate Miles - Your Love (Alex M.O.R.P.H. Extended Remix) [Suanda] 24. FEEL & Papulin & Ren Faye - The Way Of Magic (Alex M.O.R.P.H. Extended Remix) [Suanda] 25. Papulin Feat Maria Milewska - Paper Boats (Uplift Extended Mix) [Suanda] FEEL 30 Min Uplift Mix 26. Alexander Popov, Heatbeat - VIVALDI (Extended Mix) [INTERPLAY] 27. AFTERUS - Cheat Codes (Extended Mix) [TRANCEMISSION] 28. Harshil Kamdar x Robert Miles - Fable (Harshil Kamdar Extended Remix) [FREE] 29. Tycoos & Daisy Lou - Darkness Into Light [ABORA] 30. Exouler - Exouler - The Shine (Extended Mix) [SUANDA] 31. 1st in Line & Cris von X - Wash My Memories Away (Extended Mix) [AMSTERDAM TRANCE] 32. Armin van Buuren feat. Trevor Guthrie - This Is What It Feels Like (Maddix Extended Remix) [ARMADA]
durée : 00:29:24 - Les Nuits de France Culture - par : Albane Penaranda - Deuxième temps de la série "A voix nue" avec le peintre Bernard Dufour qui parle ici du sens de ses tableaux, de la peinture du réel telle qu'il la conçoit, de sa fascination pour les tableaux de Matisse, du Titien et de tous ces peintres du réel. Un tableau ne peut avoir un seul sens, une seule signification. Et le sens d'une peinture échappe à son créateur et appartient essentiellement au regardeur. C'est ce qu'affirmait le peintre Bernard Dufour dans le deuxième entretien d'"À voix nue" que lui consacrait la critique d'art Catherine Millet en 1993. La peinture énigmatique de Bernard Dufour À la question de savoir à quoi il veut contraindre le spectateur, quel sens il veut donner aux tableaux non conceptuels, il répond "ambiguïté", car "c'est vanité de ne penser qu'il n'y a qu'un sens", ajoute-t-il. La peinture conceptualiste ne l'intéresse pas du tout, au contraire de ce qu'il appelle "la peinture énigmatique" ou "peinture du réel". Dans la peinture conceptualiste il voit un sens obligatoire, une peinture programmée. Ce n'est pas ce qu'il recherche mais bien le "phénomène de pur réel". La quête du réel dans la peinture Cet entretien est l'occasion pour Bernard Dufour de dire l'enthousiasme que suscitent en lui la liberté totale, la rigueur dans le plaisir de peindre qu'il voit dans l'ouvre de Matisse, ce qu'il désigne comme la volupté de sa peinture. "Matisse est quelqu'un qui ne se délabre jamais", affirme-t-il. Peintre en quête du réel, résolument allergique à la peinture conceptualiste, Bernard Dufour salue les grandes figures de la peinture du réel qui se sont élevées "contre l'ordre idéologique de leur époque", à savoir Masaccio, Rembrandt, Goya, Cézanne, et Giacometti. Et de conclure que toute la peinture académique n'est que "trompe-l'oil". Retrouvez l'intégralité de la série "A voix nue" avec Bernard Dufour Retrouvez l'ensemble du programme d'archives Bernard Dufour, la poursuite du réel, proposé par Albane Penaranda. A voix nue - Bernard Dufour 2/5 (1ère diffusion : 04/05/1993) Par Catherine Millet Avec Bernard Dufour, peintre Réalisation Nicole Salerne Édition web : Documentation de Radio France Archive Ina-Radio France
On this episode of Five Questions Over Coffee, our guest speaker, an ESG consultant focused on social impact, emphasizes the importance of managing social risks and creating long-term value. They discuss how companies need to align social impact with business objectives, examine the key areas of people, purpose, community, and supply chain, and navigate practical challenges in implementing ESG priorities. They also explore the lack of effective communication and the importance of seeking guidance from experienced ESG consultants. Our guest shares their expertise on ESG consulting, specialization, materiality assessments, and data analytics while providing a comprehensive, globally recognized framework for responsible business conduct. The speaker offers advice and insights into understanding sustainability, ensuring social impact aligns with business objectives, and the biggest challenge of effectively integrating ESG considerations into employee engagement. Join our host and guest to hear more about managing social risks and achieving long-term value through ESG consulting.Who is Therese?Therese Baptiste is an ESG consultant who specializes in managing social risks and opportunities for her clients' products, processes, and services. She believes that a company's brand value heavily relies on its customer relationships and workforce, making it vital to manage social risks effectively. However, with no globally accepted benchmarks for social topics, it is hard to ensure consistency and comparability across ESG as a whole. Hence, companies face increasing pressure from stakeholders to display social responsibility by addressing issues related to human rights, labor practices, diversity and inclusion, community development, and customer privacy. As a consultant, Therese works with her clients to identify, prioritize, and manage social risk and opportunities aligned with their business objectives. She guides them by understanding their perspectives and developing strategies and programs to provide long-term value for multiple stakeholders, not just shareholders.Key TakeawaysTopics covered in the episode:- Overview of ESG consulting and social impact- Lack of globally accepted standards and consensus across ESG- Pressure on companies to demonstrate social responsibility- Role of ESG consultants in identifying, prioritizing, and managing social risks and opportunities aligned with business objectives- Challenges in ensuring social impact aligns with business objectives and provides long-term value for all stakeholders - Specializing in a specific area of ESG consulting and the need for materiality assessments, targets and metrics, and data analytics- Different skillsets required for analyzing the E and G aspects vs. social impact- Importance of seeking guidance or checking progress - The impact of UN Guiding Principles on Business and Human Rights - Key areas for a company to examine, considering people, purpose, community, and supply chain- Challenges in implementing ESG priorities, including lack of clarity, difficulty in measuring and reporting ESG performance, and limited resources - Need for employee engagement and effective communication- Importance of managing social risk and creating long-term value - Failure to align social impact with business objectives and narrow, short-sighted views - Insufficient data collection and analysis toolsBullets under each topic have been provided in the main text.Valuable Free Resource or ActionConnect with Therese - https://www.linkedin.com/in/therese-baptiste-cornelis/ A video version of this podcast is available on YouTube :https://youtube.com/live/6gP28ro_axA_________________________________________________________________________________________________Subscribe to our newsletter and get details of when we are doing these interviews live at https://TCA.fyi/newsletterFind out more about being a guest at : link.thecompleteapproach.co.uk/beaguestSubscribe to the podcast at https://link.thecompleteapproach.co.uk/podcastHelp us get this podcast in front of as many people as possible. Leave a nice five-star review at apple podcasts : https://link.thecompleteapproach.co.uk/apple-podcasts and on YouTube : https://link.thecompleteapproach.co.uk/Itsnotrocketscienceatyt!Here's how you can bring your business to THE next level:If you are a business owner currently turning over £/$10K - £/$50K per month and want to grow to £/$100K - £/$500k per month download my free resource on everything you need to grow your business on a single page :It's a detailed breakdown of how you can grow your business to 7-figures in a smart and sustainable way————————————————————————————————————————————-TranscriptNote, this was transcribed using a transcription software and may not reflect the exact words used in the podcast)KeywordsESG consulting, social impact, brand value, customer relationships, workforce, global standards, social responsibility, social risks, reputational damage, legal issues, financial losses, stakeholders, business objectives, sustainability, UN courses, environment, governance, materiality assessments, data analytics, internal biases, graduate advice, GRI standards, labor practices, human rights, diversity and inclusion, community engagement, customer privacy, GDPR, pandemic, employee engagement, resistant to change, effective communication, social responsibility efforts, ESG consultants, social risk management, stakeholder engagement, data collection, analysis tools.Therese Baptiste [00:00:21]:Hello.Stuart Webb [00:00:23]:It's not rocket science questions over coffee. I cannot tell you how much I'm looking forward to today's conversation. Tariff is an ESG consultant. She has got a really interesting history. Really love her history of what she's been doing. But we're not going to sort of get her to give all of her history today, her career history. But she has had some really interesting roles in Path. But she's got a really great understanding of the sustainability aspects of ESG consulting. And I really am looking forward to her describing in more detail some of that sustainability. Therese, thank you so much for spending a few minutes with us and taking your time today. I'm really looking forward to this conversation.Therese Baptiste [00:01:13]:Okay, thank you for having me.Stuart Webb [00:01:16]:And I hope you've got your coffee ready. I've got my favorite bear mug in front of me at the moment.Therese Baptiste [00:01:22]:Fresh brewed coffee served here, but it's cooked zero inside of it.Stuart Webb [00:01:27]:I love it. Listen, Deris, you help people with their ESG journey, particularly as we sort of talked about that sustainability. So who are the sort of businesses you're currently trying to help? And I know you've got some really interesting stories to tell you.Therese Baptiste [00:01:42]:Well, the thing is, for me, I really look at clients because, like I said, I do ESG consulting, but it's more of the S, the social impact. So I'm looking my clients are those who want to manage the social risk and opportunities of their product or their processes or services. And the value of most, if not all brands, I say, sits heavily in the S focused area, and that is customer relationships and your workforce. So it's easy to see how this can be getting the wrong side and can destroy a corporation's value. And what has happened is that there is yet no globally accepted. I know everyone knows about the Task Force for Climate Financial Disclosures, but there's none for social topics. And to add to this lack of comparability and consistency, the lack of the global consensus across ESG as a whole is causing a lot of problems. So what I find, companies are facing increasing pressure from stakeholders to demonstrate their social responsibility and to address issues related to what we say human rights to labor, to practices diversity and inclusion. Everyone is like, oh, we practice diversity. It's on everyone's front page of their website. To community development, truly recognizing your role in the community and customer privacy, because failure to manage these social risks effectively can lead to a reputational damage, legal and regulatory issues, and even financial losses. Okay, so again, my role would be to help my client identify, prioritize, and manage their social risk and opportunities. And there's a way I do it. And as a consultant, I will provide the guidance and the support necessary for them to achieve these goals by understanding their perspectives. So I go in, I speak to them, develop strategies and programs that align them with the company's overall business strategies. And therefore, the biggest challenge is to ensure that their social impact actually aligns with their business objectives and that they're able to manage their social risk and opportunities effectively to give long term value for all stakeholders, not just shareholders. Stakeholders?Stuart Webb [00:03:52]:Yes, stakeholders is important in that respect, isn't it? Because so often we focus on the shareholder aspect of things and forget that stakeholders involve the community, the employees, a group of people that are often neglected in many of these things.Therese Baptiste [00:04:08]:Yeah.Stuart Webb [00:04:10]:Tell me some of the mistakes that I know you have come across that people try to do in this journey that fail to really encounter and work through some of that impact that you've been talking about.Therese Baptiste [00:04:28]:Yeah. The thing is some people believe oh, I don't need an ESG consultant, I can do it myself. The mistakes are like one, focusing only on compliance so they only do what they have to do. Two, ignoring stakeholder perspectives. They don't care what the community says. Lack of integration with business strategy, insufficient data collection and analysis and failure to communicate effectively. If you wish, I can go more in detail or I can just stop there.Stuart Webb [00:04:57]:No, please give us a bit more detail because I think you've given us some really great ones there. I'm particularly concerned myself about the lack of integration with business strategy because I find so many of these there is a great deal to be said for integrating with your business strategy. And people will often just turn around and go, we've got to tick a box or let's just do something. And it's not integrated, it doesn't help to build the business. And then it does lead into a failure to communicate effectively. What can you give us in terms of pieces of advice around those subjects?Therese Baptiste [00:05:34]:Well, I'll start with the one you went with. So it's lack of integration with business strategy. What we see is that companies may view social responsibility as a separate and distinct aspect of their operations rather than an integral part of their business strategy and this can result in a failure to align social impact with business objectives and a missed opportunity to create that long term value. And I started off with focusing only on compliance. That was my first one, focusing only on compliance. Many companies, they make a mistake of focusing solely on compliance with regulations and laws related to social issues without considering the broader social impact of their operations. I mean, there are some laws that said no child labor involved and they said okay fine, no child labor. But then they go and they want to make their products in countries where child labor is the norm. So rather than saying okay fine, if we don't hire those children, someone else would and saying let's see how we can work with this law. No child labor. Really? What is the intent of that? The intent of it is really that we want children to be educated. And there are some companies who have managed to say, fine, I will hire your child. Your child can work for a maximum of 2 hours, but they must go through four or 5 hours of education per day and the company pays for it. So it's more like in the curriculum as such. Again, if you just go poopy on compliance, it can be a narrow, short sighted view, and it doesn't serve the purpose of helping the community. If we look at ignoring stakeholder perspectives, companies may fail to engage with key stakeholders such as their employees, their suppliers, their customers, and their communities to understand their perspectives and their concerns related to social issues. So they just go with what the law says they have to do. The law says, okay, fine, we must like, I saw like there were some people wanted to say, let's say 10% of your company must be diverse. If you just look at that, 10% must be diverse. Some people interpret it to be of a different race, but that is fantastic if that reflects your environment where you operate of having that percentage. Because I teased one person, I was talking to a company and they were like, yeah, that's a good thing to do. But then one person in that group was actually from a company based in Africa. So I said to him, so are you getting 10% of people there of North African descent? And he looked at me like, of course not. I said, but if you want to make this a global thing, it has to be that way. So again, we see. This can lead to a lack of understanding of the social risk and the, I say, opportunities that a company faces and the potential impact on its reputation and financial performance. Like, I tell people, yes, I understand we want to get gender inclusivity, but will I hire someone just because they're female? No, if they have the qualifications and stuff. So, I mean, don't just tick the box, really implement it. Then we talk about insufficient data collection and analysis and oh my God, we don't have the data, and we make all these assumptions. Companies may lack the necessary data collection and analysis tools which exist out there, but you have to look through to see which ones apply to you, which one are built. I always remember when I first started doing business process reengineering straight out of university back in 1994, and that was the big buzzword. And at that point they said that you need to have 99.9% no errors. And I went to a client and the client was, okay, we want to make sure that we have 99.9% no errors. And I was like, you do 100 transactions a day. In other words, you can't have any go wrong. That is what it means. You can't use that as your measuring tool. So this can lead to incomplete understanding of social risk and opportunities, making it difficult to develop strategies they must be logical and able to implement. If you come up with metrics and try to implement them without data that matches what your company does, you literally excuse the word screwing yourself out of the systems. Right?Stuart Webb [00:09:52]:I have to ask about data thing because I had a client once who told me that they were bringing some machine learning and they were going to use some data in order to improve their process. And I said, okay, so from where are you gathering this data? And they said, well, we're not gathering it yet, we're going to start gathering it. And I went, okay, when are you going to implement the machine learning having gathered the data? And they told me they were implementing machine learning at the same time. And I went, but that doesn't work because you won't have the data to train the model. And they went, oh, don't worry, we're going to make data up. And I looked and I thought, I worry about the fact that companies actually.Therese Baptiste [00:10:27]:Do think these are the thing is my problem. I come from a background of It. My first degree was mathematics and computer science. I only went on to do business studies because I couldn't speak business speak and the business people couldn't speak tech speak. So now I call myself a perfect bridge. So I can understand when the techs are trying to throw wool over your eyes and also to when the business people are asking for things that are impossible given the circumstances. And the last thing and that comes, it failure to communicate effectively. Companies fail to effectively communicate their social responsibility, efforts and impact to stakeholders. And if you don't tell people what you're doing, don't expect them to know, okay? They lead to a lack of trust and confidence in the company's commitment. It's not blowing your own horn, but recognize that I'm doing good, let them know what you're doing. Bad news travels faster. You got to keep ahead by telling them what you're doing good. So those are the kind of things I teach to companies. Keep it out there because again, when I was doing my Masters, I did technology. Yeah, why not, right? Because it was easy to continue onwards. But I took marketing and strategy as the three subjects I were looking at, simply because marketing, getting that brand, that communication out there is all strategy with technology. So I consider myself, oh yeah, I got the blend and that is what needs to go there. So you have to manage the social risk. If you want to manage it without the help of an experienced ESG consultant, you're going to end up with a piecemeal approach that fails to effectively address your company's social impact. It's crucial you seek guidance and support from experienced ESG consultant, not those who have done an ESG course. There's too many courses out there and I see people, I look in this and they say they've done a course and they're ESG consultant. They haven't even lived life yet, right? Stewart they barely have. Like you said, you can still see the baby eyes and everything, but no, they're the consultants. I've gone to meetings with other ESG consultants and then when I'm speaking, they look at me like I was like, We've lived it. Stuart like I said, as I go further, you will realize this is not something new. It's just keep new terminologies that come out, new buzzwords that come out. It's crucial companies seek the guidance of an experienced person to ensure they're managing their risk and opportunities effectively to create that long term value.Stuart Webb [00:13:00]:Because for me, one of the signs of a good consultant is not that they've done 15 implementations, but they've done twelve, and three have gone badly wrong. And they won't make those mistakes again because they don't want to live through that pain ever again. And I often say to people, when they sort of say, well, why should I hire you? And I said, I've made all the mistakes so you won't have to. And that's the secret of being a good consultant, is to turn around and be honest and say, I've made enough mistakes that I now know what not to do. And I'll make sure you don't actually make those mistakes because I don't want to have to live through that experience ever again. You were talking then about some great ways of helping people to understand sort of some of these things. And I know you've got a really valuable free piece of advice, which I'm just going to show at the bottom of the screen. So can you talk to us about this valuable piece of free advice that.Therese Baptiste [00:13:54]:You'Ve sort of yeah, because you were asking me in our little talk before about what valuable resource people can go to because not everyone, I agree, can afford to hire an ESG consultant. Do I have to admit to Raspberries.com I'm not that expensive compared to the others from the so called firms who really inflate their cost? Okay. One valuable free resource I can recommend to people looking to manage is the Global Reporting Initiative Standards. The link is there for you that Stuart has given you. It provides for you a framework for companies to report on their sustainability performance. It provides guidance on how to report on a range of social issues because you have to report on your labor practices, on your human rights. Yeah, your human rights. What are you doing to the people in your company, people around people around the world? Diversity and inclusion, community engagement, customer privacy, GDPR and data security. Okay. Because those are things you look at. Even as far as passwords. I mean, just today I got a message from someone showing me according to how many words and characters in my password, how long it will take a hacker to hack. Okay? So now I have realized I need to develop a 14 word password. 14 words. I used to have eight or 914 words password with numbers lowercase and so on, and then it will take them some years. Other than that, it was five minutes, so I thought I was good. But apparently now the hackers are getting better. So by following the Gir standards, companies can ensure they're collecting and reporting on relevant data and information related to their social impact. Okay? Because remember, we have a lot of stuff about the climate and I could go on Stewart about green washing, but that's not my area. Just like this green washing, there's a lot of social washing pretending to care for people. Okay? The GI standards are a valuable free resource because they're publicly available and can be used by any company regardless of size or industry. Okay? It's widely recognized if you use it, companies can improve their understanding on their social impact and skills, develop strategies and programs. It can help them create long term value. But like I said, it's always best still to get. You don't have to get an ESG consultant like myself to manage the entire project, but it's normally helps when you start in guidelines or to check in on what your people are doing. Is it on your right path because you don't want to wait till 2025 when everyone's supposed to be ready to realize, I did it on my own and I did it wrong. Like when you baked that cake that you never followed in directions for, but you saw it in a book and you figured everything was there, which never is, and your cake doesn't come out the way it's supposed to and you only find out when you serve it to the guest. You don't want to do that.Stuart Webb [00:16:48]:Yeah, they'll help you make sure you never make those mistakes again because nobody wants to live through those sort of mistakes, do they, Teresa? No. There must have been a concept that you came across which really fired you up towards sort of this passion you've got for the social impact that your enterprise can have. What is it? What do you recommend that we read or get into in order to be able to understand and get into the passion that you've got for the subject?Therese Baptiste [00:17:21]:Well, then we are going back to one of my positions. I held, not tooting my own horn. I was my country's UN ambassador based in Geneva, and I was on the UNHCR committee. And that was when I was first exposed to the UN guiding principles on business and human rights. And I was like, literally, I was a business lecturer at university and I had not been exposed to how in depth this was. People have sat down and developed this. There are set of international standards that provide guidance to companies on how to respect human rights in their operations and supply chains. Okay. The Guiding Principles establish responsibility of companies to respect human rights, the need for companies to conduct due diligence to identify and address human rights. This sounds familiar, right? This is all what ESG and all these things are saying. This existed before the importance of providing access to effective remedies for human rights violations. I mean, I was so much into it when I was recently lecturing at a local university based in Belgium. We had students in final year, and one of the topics I had my students research was human rights. And at the beginning, they were like, human rights business. And then they saw the major impact and they saw the linkages. They had never seen that document. And it was so great to see these students dwell into it and develop research looking at technology and human rights. And for a senior ESG consultant focused on the S in ESG, I would say the UN Guiding Principles provides a comprehensive, globally recognized framework. It incorporates if you look at the ESG consultants, we help clients develop and impact human rights policies. Right. We see right now there's a lot of confusion with is EU policies for human rights for ESG really focused on the correct thing, or is it what looks good for the finances and people don't realize? The UN Guiding Principles has been implemented and is the key thing for responsible business conduct. It has been used by OECD in guidelines for their multinational enterprises. It has been used by IOL for their triparty. Declaration of Principles Concerning Multinational Enterprises and Social Policy It has also been used ISO 26,000 for guidance and social responsibility. It has been a transformative concept in ESG. And that's why I go back to her to say in ESG, it's coming from there. Okay, so, yeah, I was a UN ambassador back in 2011, 2012. So it sounds over 1112 years ago, I've been in this sustainability thing. I even served as the vice president on the UN Forum of Sustainability Standards. I was like the only diplomat at that time because I was a diplomat. I had been a minister of health. Yeah. Another thing, a politician. I've been an academic, had been in business. So they wanted that kind of background to see because to give that Holistic approach. And it provides what we consider to be a framework for managing social risk and opportunities related helping establish global standards. Because as I said in the beginning, there's nothing out there ready. There's no agreed on global principles. We don't have someone like Bloomberg, who is the head of the Task Force for Climate Financial Disclosures pushing on the social impact. We need someone to take that mantle and push on it, someone high profile who people respect the social impact. Okay? And we see that what we call the UNGPs. The UN guiding principles has helped develop the S component.Stuart Webb [00:21:01]:Ask you the first question before I do, I'm just going to suggest I know there are a couple of people watching at the moment. I'm just going to ask, if people do have questions, please post them in the chat. And I can ask them. Theresa now, because she's got some really valuable experience and as you've heard, she has a sort of background of taking a lot of input from politics to social impact and working with the UN. And some of that might give you what might give you problems. I know that I wouldn't want to do half of those things, but it might provide a lot of opportunities for people to say so if there are questions. But whilst we're just doing that, I'm just going to pose the final question that I've got for you, Teresa.Therese Baptiste [00:21:50]:It's an easy one. It's going to be an easy one.Stuart Webb [00:21:55]:I always use this question in order to sort of not have to do too much work. So it's quite honest. I have been asking you some questions, you've been having to answer them, but there must be a question which I haven't answered, which you would like me to answer. So what would you like me to have said? What question would you like me to have asked you, which I haven't yet? And obviously you have to answer it.Therese Baptiste [00:22:19]:Thank you. I would say you should have asked, what are the key areas for a company to examine who's looking to consistently meet the requirements and expectations of their stakeholders? Now, I'm going to answer that. I have two questions, actually, but that's my first one. I would think they would have to look at people. Yeah, why not? We must. People can't do math, people purpose, community and supply chain. Those are the four key areas, I would say people, because the pandemic something like don't Ranch on the pandemic again, Ms Matisse, the pandemic has changed the way we work. And with more working from home, it has shone the light on people's. Wellbeing, it really has. Therefore, companies will need to communicate clearly what staff support is going to be available. And there's also a job to close the gap between those at the top of the workforce and the millennials. The millennials are willing to grasp, want to work in at home. We still have some of the older people that believe, if I don't see you, you're not working. And again, I was never that way. I mean, even when I worked at a bank, I always told people I worked at the bank and I had younger I shouldn't say younger, older people underneath me. Right. But they consider themselves younger. But my logic was I didn't check what time they came in or what time they left. I gave them an assignment. They could come in one day every week, but if that assignment was finished, good, because I don't believe in watching every hour, because some people work very good quickly and then need a time off, right? And the FRC Reporting Lab has released what they call useful guidelines on workforce reporting including the importance of workforce engagement. Okay? And engagement doesn't mean because they're working from home, having nonstop meetings online. That's not it. If we look again at purpose, I think it's businesses need to create value, okay? Don't assume you're creating value and address these issues. Investors, because ESG came about primarily to make people invest in your companies. Okay? Everybody knows it's money. Everything is not going to be done unless there's money to be seen in it. And investors want to see companies believe in something and more than ever link the purpose and trust is dominant. It's a key requirement and I think it's also in your UK corporate governance code, key to building trust. It is essential for companies to think about demonstrating how their purpose drives what they do and the impact they have. The third thing I said was community businesses should be able to demonstrate how they tend to support or add value. So you need to look at that and supply chain, consider your ecosystem. And again, I remind, I mean, most people here wouldn't know, but there are some people who think that ecosystem talks only about trees and the forest. Ecosystem is the area of the businesses operating. And we say of your business, who you are to be an employee versus a contractor. Who do you want as your employee? Which ones can you say? Okay, I don't need this person as an employee, I need them as freelance. I give them opportunities to have other projects because that is sometimes why in your supply chain you have to look at do I need someone nonstop or do I need someone for projects? Because there are people willing to a lot of people are realizing the value of being a freelancer, okay? It's given them that control over their lives. They all have an impact on your brand and reputation because again, if you take someone just as a contractor as opposed to an employee, you don't again have full control and again what they do can impact on you and we talk about all those issues. And your business only operates well if all parts are healthy. Okay? So that comes back to my Minister of Health part. Everything needs to be healthy working together. Nothing can be a silo on its own. Okay? And a question that would have opened up more. My 6th thing is what do I see as the biggest challenge for companies to effectively integrate ESG considerations and how can they overcome this?Stuart Webb [00:26:33]:Well, I've asked you that but I didn't want you to feel under any pressure, honestly.Therese Baptiste [00:26:38]:I know because again, when I thought about it, I said if I answer this, that might reduce the need for them to hire terrestrial.com, right? Should I put that question? Because then it will have all the ESG consultants about how we support companies in this process. But I'm going to be honest and I'll just give you the four things. The several practical challenges that companies face is lack of clarity and consensus on their ESG priorities. There's a lack of clarity and consensus. There is difficulty in measuring and reporting on ESG performance and again that is where I do advise you to bring in someone who can make that so much simpler for you. I always tell people stick to what you're good at okay? Too many people are just taking ESG reporting and saying hey that's your job and throwing people into the wind and then wondering why it's taking so long, why it's not getting done. Okay? Limited resources and capacity if you have limited resources and capacity in your company recognize that. Put those limited resources and capacity where it makes money for your company and hire another resource to deal with it. And I go back to for instance when I lived in Trinidad and my husband and I had our company called Cornells and Associates. I used to really find it. It was strategic but it was funny. At the same time we were being hired by a leading accounting company to run their website. We were being hired by them to develop a strategic plan for them. Meanwhile they were hiring their consultants out to people to develop website. And I said to the managing partner I said you know something you not hire me because I'm that better than your employees but you can get more money from sending them out than I would charge you. And he says you know and I said yeah because I work for you I know what rate you charge thing but I don't charge that to you. So they can get me for 50% of what they would charge. So they make a lot more money off of it. But then they know that is it limited resources. They need something done. They want an outside perspective someone with a clean with no bias in it. And that is a problem if you take too many internal people to do that reporting they may have an internal bias, they may have it and they don't see anything wrong with the way it is operating now. So it can easily fix the report to say all is okay but then when the audit comes you're going to be in problems when the audit comes because what is reported is not true. And again be careful of the internal silos and your resistance to change. As people we don't like change.Stuart Webb [00:29:29]:Owners directors who spend a lot of their time doing things actually they ought to get other people to do partly because it's more effective and they pull a bigger growth lever by getting on and doing something which produces better results. But also because their internal bias means that they make decisions based upon what their gut tells them and their gut is often. Very wrong. It doesn't involve the right data. They haven't collected the data. So they go on what they think is the right thing. And I see a lot of decisions being taken by people who don't have the data but have decided to. As I sort of said before, they guessed what they think it will be, and they end up making a lot of mistakes, largely because they haven't brought somebody in from the outside who's able to take a fresh view. And just look at it and go. But it's obvious because I can see things here that you can't see because you're inside looking out. And I've come in from the outside so often. We do need to have that perspective of somebody who can just take a fresh view. Theresa, I just want to ask one question. We've had one question from Mark Thomas. I think it's a really interesting one that I would love you to just give. And perhaps you need to link with Mark Thomas outside of this, but can you just give him two minutes? And I don't want to take up too much more of your valuable time, because I know you have actually got a lot of things you want to try and do today, but what advice do you have for a graduate who wants to get into this field? And I think encouraging young people into this field is absolutely critical to the future.Therese Baptiste [00:30:56]:Yeah. And the thing is, one of these main things is if you're going into the field of ESG consulting, then you really have an interest in sustainability. Okay? It's not just finance, it's sustainability. The UN has a lot of sustainability courses to give you that background, the connections of it, not just the financial part, depending on your angle, which one is more for you? Are you one for environment? Are you one for social impact? Or you want for governance? Because the problem is when people try to say, I'm an ESG consultant of all, okay, because that is where it's problematic. So I would say Mark Thomas, because if you go out and you have to help them conduct materiality assessments, okay, you have to help them set clear targets and metrics. You have to help them do data analytics. So if you will, I see you see background in financial computing will understand I wouldn't see you doing more the social impact, but you can analyze it and do the comparison, but I definitely see you more in looking at the E and the G would be for somebody in finance. So, again, understanding sustainability and what it means, it doesn't just mean, okay, I don't use disposable, I don't do this. It's really understanding how these things interact, realizing that there is no perfect utopia that we want to create. If we create this perfect utopia, we are creating it for a few people because you can't get rid of everybody goes electric cars and stuff like that. So you're going in there with an understanding that you can't fix their problems, but you can help them understand their problems. And that is what a graduate needs to do. Okay, brilliant.Stuart Webb [00:32:48]:Theresa, you broke up a little bit on that question, but I think we absolutely got the spirit of it. And if people want to sort of get a message to you afterwards, I'd encourage you to please post them into this post on LinkedIn YouTube. We will get them to Theresa. She's just fond of knowledge and so much enthusiasm. Theresa, I want to thank you so much for this time you've spent with us. It's been brilliant. I really, really have enjoyed it. I hope everybody watching has enjoyed it. I'm just going to leave you with the one final link on this, which is if you want to get onto the newsletter list so that you get notification of this thing coming up. Coming up in the next few weeks. I would encourage you to just go onto this link, which is link thecompletroach Co UK newsletter that's link thecompleetproach Co UK newsletter that will get you onto our newsletter list. We send out a newsletter which basically says who's coming onto the podcast so you can join our questions, get them answered by people like theres Mark Thomas. I hope that's been useful to you. When you get advice from somebody as knowledgeable and ingrained in this and is so much of an expert, you can't get better advice. Theresa, thank you so much for spending a few minutes with us. Really appreciate it. My pleasure, everybody. I just really appreciate the amount of time that we've had Therese on today. I hope you have, too. Thank you.Therese Baptiste [00:34:17]:Thank you.Stuart Webb [00:34:19]:And we'll just make sure everything works on the podcast before it all goes horribly wrong on me. Get full access to It's Not Rocket Science! at thecompleteapproach.substack.com/subscribe
01. Martin Garrix & Seth Hills - Biochemical (Intro Edit) [STMPD] 02. Seth Hills - Eclipse [STMPD] w/ Benny Benassi pres. The Biz - Satisfaction (Acappella) [D:VISION] w/ Zedd & Lucky Date ft. Ellie Goulding - Fall Into The Sky (Everybody Fuckin Jump Acappella) [INTERSCOPE] 03. Martin Garrix & Mesto - Chase Me [STMPD] w/ Tiësto - Lethal Industry [MAGIK MUZIK] w/ Martin Garrix ft. John Martin - Higher Ground (Acappella) [EPIC AMSTERDAM/STMPD] 04. Lewis Capaldi - Someone You Loved (Martin Garrix Remix) [VIRGIN] 05. Martin Garrix & Third ≡ Party - Flashlights [STMPD] w/ Nico & Vinz - Am I Wrong (Acappella) [WARNER BROS.] 06. David Guetta & Martin Garrix & Brooks - Like I Do [PARLOPHONE] 07. FISHER ft. Kita Alexander - Atmosphere [CATCH & RELEASE] 08. MAKJ ft. Maria Cardona - Worship [SPINNIN'] w/ Mightyfools - Footrocker (Get Your, Get Your Hands Up Acappella) [REVEALED] w/ Nari & Milani - Atom (Blast Beat GO Acappella) [SIZE] 09. Bingo Players - Devotion [SNEAKERZ] w/ Julian Jordan & Martin Garrix ft. Tinie Tempah - Diamonds [STMPD] 10. Martin Garrix & MOTi ft. Jenny Wahlström - Virus (How About Now) [SPINNIN'] 11. ID - ID w/ Ivan Gough & Feenixpawl ft. Georgi Kay - In My Mind (Acappella) [AXTONE] 12. Martin Garrix - Animals [STMPD] w/ Martin Garrix & Blinders ft. Ilsey Juber - Breach (Walk Alone) [EPIC AMSTERDAM/STMPD] 13. Tiësto & The Chainsmokers - Split (Only U) (Cheyenne Giles Festival Flip) [FREE/MUSICAL FREEDOM] 14. Martin Garrix & Mesto vs. Dua Lipa - Limitless vs. Scared To Be Lonely (Martin Garrix Mashup) [STMPD] 15. Martin Garrix & DubVision - Warriors [STMPD] w/ Martin Garrix ft. Khalid - Ocean (Acappella) [EPIC AMSTERDAM/STMPD] [32:08] Avicii ft. Simon Aldred - Waiting For Love [PRMD] w/ Martin Garrix vs. Dimitri Vegas & Like Mike vs. Avicii ft. Simon Aldred - Tremor vs. Waiting For Love (Martin Garrix Mashup) [SPINNIN'/PRMD] 16. Sander van Doorn - On A Roll [FUTURE RAVE] 17. Avicii ft. Aloe Blacc - SOS (Lucas & Steve Remix) [UMG] w/ Martin Garrix & Brooks - Quantum [STMPD] 18. Martin Garrix ft. Bonn - High On Life [EPIC AMSTERDAM/STMPD] 19. Martin Garrix & Sentinel ft. Bonn - Hurricane [STMPD/TOMORROWLAND MUSIC] 20. Martin Garrix & Breathe Carolina - Something [STMPD/TOMORROWLAND MUSIC] 21. Swedish House Mafia vs. Tiësto vs. Don Diablo vs. Mightyfools - One vs. Grapevine vs. Eyes Closed vs. Footrocker (Martin Garrix Mashup) [POLYDOR/REVEALED/MUSICAL FREEDOM/HEXAGON] w/ 070 Shake - Cocoon (Martin Garrix & Space Ducks Remix) [GETTING OUT OUR DREAMS/DEF JAM] 22. Bassjackers vs. Afrojack & Martin Garrix - Like That vs. Turn Up The Speakers (Martin Garrix Mashup) [SPINNIN'/SMASH THE HOUSE] 23. ID - ID w/ Jamie Lewis ft. Michael Watford - For You (Put Your Hands Up In The Air Acappella) [PURPLE MUSIC] 24. Martin Garrix & Matisse & Sadko ft. John Martin - Won't Let You Go (Eleganto Remix) [STMPD] 25. Martin Garrix & Zedd ft. Emily Warren - Follow [STMPD] 26. Alesso & OneRepublic vs. Coldplay - If I Lose Myself vs. Fix You (Alesso Mashup) [PARLOPHONE/MOSLEY] 27. Martin Garrix & Third ≡ Party & Max McElligott - Lions In The Wild vs. Poison (Martin Garrix Mashup) [STMPD] 28. Swedish House Mafia vs. Martin Garrix & Tove Lo - It Gets Better vs. Pressure (Martin Garrix Mashup) [EPIC AMSTERDAM/SSA] 29. AFROJACK - Polkadots (Space Ducks Remix) [WALL] 30. Ill Phill & Mesto vs. Sikdope - Seven Nation Snakes (Martin Garrix Mashup) [FLY EYE/FREE] 31. Martin Garrix & Bebe Rexha - In The Name Of Love [EPIC AMSTERDAM/STMPD] w/ Martin Garrix & Blinders vs. Bebe Rexha - Aurora vs. In The Name Of Love (Martin Garrix Mashup) [STMPD] 32. Martin Garrix vs. John Martin - Higher Ground vs. Forbidden Voices (Martin Garrix Mashup) [SPINNIN'/EPIC AMSTERDAM] w/ Martin Garrix - Forbidden Voices [SPINNIN'] 33. Julian Jordan vs. ACRAZE & Cherish vs. Benny Benassi pres. The Biz - Rudeboy vs. Do It To It vs. Satisfaction (Julian Jordan Mashup) [D:VISION/THRIVE MUSIC/STMPD] w/ David Guetta vs. Benny Benassi - Satisfaction [SPINNIN'/ULTRA] 34. Martin Garrix X JVKE - Hero (DubVision Remix) [STMPD/EPIC AMSTERDAM] 35. Nicky Romero & Teamworx vs. Mightyfools vs. Martin Garrix & Jay Hardway - Champion Sound vs. Footrocker vs. Spotless (Martin Garrix Mashup) [REVEALED/EPIC AMSTERDAM/PROTOCOL] 36. Martin Garrix & Bonn vs. DubVision - No Sleep (Martin Garrix Mashup) [EPIC AMSTERDAM] 37. Martin Garrix & DubVision ft. Shaun Farrugia - Starlight (Keep Me Afloat) (Outro Edit) [STMPD]
New Packaging, Same Delicious Flavor. ExZac, Cody, Matisse & Brennon talk best burger spots around Spokane, Submarine Voyages, and Reality TV. The group also eats exotic whip cream, and Brennon says HELLO. --- Send in a voice message: https://podcasters.spotify.com/pod/show/happy2bherepod/message
Rdv avec la réalisatrice, photographe et scénographe Leïla Sy. Véritable Légende dans le monde du rap, elle a su imposer en 20 ans de carrière son style, sa créativité et son regard affûté auprès des plus grandes stars du genre : Kery James, Vald, Tunisiano, LEJ, Lino, Rockin Squat, Fianso, Nassi, Medine, Bilel Hassani, Chilla, Keny Arkana, Yaniss Odua, Gaël Faye, Diam's, Seth Gheko, Wax Taylor, Jul, Dadju, Lyna Mayem, DjaDja et Dinaz… Retour sur son parcours atypique et impressionnant de ses études à Penninghen jusqu'à la co-réalisation de longs-métrages dont « Banlieusards » aux côtés de Kery James ou « Yo Mama » avec Amadou Mariko (sortie 5 juillet 2023). Dans cet épisode, le rappeur sénégalais Nix pose la question surprise.Retrouvez sur la chaîne YouTube de Légendes Urbaines la version longue de l'émission avec en bonus les vidéos surprises de Matisse et Khalil (ses fils) et Zaho, ainsi que le billet d'humeur d'Aimeric Alias Krow.
Drs. Diwakar Davar and Jason Luke discuss KEYNOTE-716, KEYNOTE-942, RELATIVITY-047, and other key advances in melanoma, including the promise of mRNA vaccines in melanoma and potentially other cancers, as well exciting advances in neoadjuvant therapies across malignancies featured at the 2023 ASCO Annual Meeting. TRANSCRIPT Dr. Diwakar Davar: Hello, and welcome to the ASCO Daily News Podcast. I'm your guest host, Dr. Diwakar Davar. I'm an associate professor of medicine and the clinical director of the Melanoma and Skin Cancer Program at the University of Pittsburgh Hillman Cancer Center. I'm delighted to have my colleague and good friend Dr. Jason Luke on the podcast today to discuss some practice-changing studies and other advances in immunotherapy that were featured at the 2023 ASCO Annual Meeting. Dr. Luke is an associate professor of medicine, the director of the Cancer Immunotherapy Center, as well as the associate director of clinical research at the University of Pittsburgh's Hillman Cancer Center. You can find both of our disclosures in the transcript of this episode, and disclosures of all guests on the ASCO Daily News Podcast are available on our transcripts at asco.org/DNpod. Jason, there was a lot of exciting data in the immunotherapy space highlighted at the Annual Meeting, and it's great to have you back on the podcast to discuss some of this work. Dr. Jason Luke: Thanks for having me. Dr. Diwakar Davar: So, the abstracts that we had selected have several key themes. We'll be covering some of the early advances in melanoma in the stage 2 and stage 2B/C space with KEYNOTE-716. I think this is a study that you know a little bit about seeing you are the presenting author and the principal investigator for the study, as well as the pivotal KEYNOTE-942 trial. And then going on to themes with using third-generation checkpoints, neoadjuvant therapy in non-small-cell lung cancer, and cutaneous squamous cell carcinoma. But we'll start with KEYNOTE-716. So, this is LBA9505, the study which evaluated pembrolizumab versus placebo as adjuvant therapy in stage 2B and stage 2C melanoma patient population for which historically there was no real effective therapy other than remotely interferon. And these are the final results of the DMFS analysis from this phase 3 trial. So, Jason, what are your thoughts about this, and can you contextualize the results relative to the recent publication? Dr. Jason Luke: Thanks. I think the important point to level set on this was just a few years ago; this was a population of patients that we didn't treat in clinic. In fact, sometimes they weren't even referred to medical oncology for evaluation. And that was despite the fact that we knew from historical data that the risk of melanoma-specific survival, death from melanoma, was just as high for this population of patients as it was for the patients with stage 3 melanoma, where obviously adjuvant immunotherapy has been a standard for quite some time. And so we launched this clinical trial, KEYNOTE-716. It was a global, randomized phase 3 study of almost 1,000 patients, randomizing patients to either get pembrolizumab or placebo. Importantly, these patients being those with deep primary lesions, stage 2B and 2C with negative sentinel lymph node evaluation. People will recall that this study hit its primary endpoint on the first protocol-specified analysis at a year. And what we updated at ASCO this year was the final analysis of distant metastasis-free survival. Obviously, an important secondary endpoint because if patients eventually going to develop metastatic disease and pass away, it's the distant metastasis that we worry about. And what we saw in this trial with a landmark 36-month follow-up median of 39 months was that the benefit was increasing. In other words, the magnitude of the hazard ratio change was increasing over time as would be expected, such that at this analysis there was a 41% reduction in the risk of distant metastasis for patients treated with pembrolizumab versus placebo. And we saw a consistent benefit in the recurrence-free survival also out through that same period of time and importantly no change in the safety summary with of course the adverse event profile of pembrolizumab being what it is and well understood across oncology. So I think these are very important data because they really kind of set the stage for the field. It is now the case that at least discussing adjuvant therapy for patients with stage 2B and 2C is the standard of care; it should be offered to all the patients. Of course, it's always a risk-benefit about whether or not patients want to pursue adjuvant therapy versus consideration of treatment at the time of recurrence. But in my clinic at least, many patients do prefer to try to eliminate the possibility of recurrence and distant metastasis as much as possible. So I think these are very important data because they really level set the field for what to expect in this population of patients and then they also start to set the table for what's going to come after this. And that's going to be sort of the next step in our conversation here because the next generation of adjuvant studies in melanoma are now going to think about all of melanoma in the adjuvant setting as really one entity, starting from stage 2B going all the way through stage 4 resected. And that'll be relevant actually as we talk about the next abstract that will come in this discussion. Dr. Diwakar Davar: Just to underscore, positive RFS data, positive DMFS data, and now this therapy has currently got regulatory approval in this investigation and is approved in the United States and certainly in Europe and Australia. One interesting point that we will probably have to contend with, and some of the listeners may be thinking about, is overall survival. So the last adjuvant study that demonstrated overall survival benefit was actually ipilimumab, and increasingly, the Illuminati in melanoma do not believe that we will ever see OS benefit in this disease going forward, even though it has to be an endpoint in all registration phase 3 trials. So, Jason, what are your thoughts about whether or not we'll have a positive OS readout, and even if we don't, why this is still a very important advance in this disease at this time? Dr. Jason Luke: Your points are well taken. I think it's unclear, probably trending towards unlikely, that we would see an overall survival advantage in this trial given that we have not seen that in the stage 3 adjuvant studies. Now people can debate if, whether or not overall survival is the only meaningful endpoint for patients. I personally do not believe that's true. And to me, preventing recurrence has a value in and of itself, whether or not that's connected to overall survival. And part of the reason that I say that is that for an average patient, the median patient on a trial, of course, we can tell them treatment now, treatment later. It's a wash when you look at the overall study. And yet at the same time, for an individual person who's facing melanoma or cancer, generally they're not going to be the average patient; they're going to be one patient. And it's very possible they could end up with the type of recurrence that in fact is not highly treatable at that time. So I think that's really the nuance that goes into those adjuvant discussions. The regulatory endpoints have been recurrence in melanoma for a long time. And I think it's important that patients understand the pros and the cons of each. The complexity in adjuvant therapy and neoadjuvant therapy is you don't necessarily know that you had to have it. You're only really going to know whether or not it didn't work if you recur later on. But to me and in my clinic, most patients are willing and interested to want to pursue those therapies in the perioperative setting to try to reduce the possibility of ever developing metastatic disease. Dr. Diwakar Davar: Excellent. So I think key advance [is] positive DMFS data to add to the earlier reported RFS data and truly practice-changing. So, moving on to the next study, LBA9503. This is the phase 2 trial of the Moderna vaccine. This is the trial that almost every medical oncologist knows intimately or has been called about by either the press or patients. So what is this study? This essentially is a phase 2 trial evaluating the personalized cancer vaccine PCV Moderna, made by Moderna, the mRNA vaccine, that is being studied in combination with anti-PD-1 pembrolizumab in the stage 3 BCD and stage 4 resected setting. And so there are really two very interesting results here because this is an update of the RFS data that was presented at AACR earlier this year, which was positive. What are your takes on the DMFS results, and maybe a quick blurb on how is this vaccine generated for those who may not be aware of this particular platform? Dr. Jason Luke: Yeah, certainly. So this individualized neo-antigen therapy, as we're now calling it, is a technology platform that allows us to develop an individualized treatment for each patient based on their own cancer. So taking the actual tumor specimen, whole exome sequencing is performed to try to identify changes in the DNA, and then through a reasonably complex bioinformatic pipeline, those mutations that are likely to generate proteins that can be bound within class 1 MHC molecules are then identified in the computer and then synthesized with an mRNA, very similar to the way that the COVID vaccines were made. And then that becomes the actual drug. So in the clinical trial, which was KEYNOTE-942, about 160 patients were randomized 2 to 1 to receive either pembrolizumab for a year as per standard adjuvant therapy but then with the addition of the individualized neoantigen therapy starting with dose 3 and throughout the rest of the year versus the control arm of pembrolizumab as the standard of care. As you mentioned, the recurrence-free survival were highly positive in this trial when it was first presented earlier this year, and at the updated ASCO we see the 18-month RFS in which the hazard ratio continues to be maintained. But I think most impressively is that distant metastasis-free survival, where we saw an even greater advantage for distant metastasis-free survival – hazard ratio here being 0.35. And so that's a huge advantage for distant metastasis-free survival in this population of patients. And very interestingly in the clinical trial, when you follow the Kaplan-Meier plots, what you see over time is that they overlap almost the entire first year. And it's really at about a year, basically after the vaccine has had time to kick in and these neoantigens have been identified, that we then start to see the separation of the curve, which looks very flat over time. And so I think this is a very, very exciting kind of technology platform and very exciting results because there was minimal increase in toxicity – just at the site of the local injection – for the addition of the individualized neoantigen therapy. And beyond that, hypothetically, this is not necessarily just a melanoma thing. So, of course, based on these phase 2 results, a phase 3 clinical trial called KEYNOTE-V940 is going to be launching later this year to compare pembrolizumab versus pembrolizumab plus this V940 individualized neoantigen therapy. And we're very, very excited in the field to see what those results will look like because the concept here is you could really, really enhance adjuvant therapy with this kind of an approach. Meanwhile, we're just about to talk in a little bit about all the exciting things happening in the neoadjuvant space as well. And with no increase in toxicity, obviously, that looks really good. Suffice it to say that this technology is not specific to melanoma but rather could be applied almost to any cancer where we think about an adjuvant therapy platform. So I think the results are very, very exciting. It is a phase 2 study and it does have some caveats about not being the largest study and some other things, but you can't help but be impressed by the data that have been presented here so far. Dr. Diwakar Davar: One important plug, I guess, in addition to that is that you mentioned that there's data using the platform in other diseases. And one really exciting paper that came out recently was Dr. Vinod Balachandran's paper; for those who haven't read it, it's in Nature, and really in a very provocative proof of concept study, they studied the platform, the vaccine plus checkpoint inhibitor therapy plus chemotherapy in a highly adverse tumor patient population. So these are patients with resectable pancreatic cancer who had the vaccine generated from pancreatic cancer that was resected after Whipple surgery. And extraordinarily, out of the 16 patients who had immune responses, 8 of them did not have relapse at a median follow-up of almost a year and a half, which is really quite extraordinary given the lack of really any effective drug outside of chemotherapy in that setting. So, the point that you're making regarding the benefit of this therapy, suggesting that it could potentially be extended to not just melanoma, potentially other tumors such as highly immunogenic tumors, and potentially even nonimmunogenic tumors such as pancreatic cancer, really suggests that this is going to be a very exciting landscape. And potentially this area, adjuvant therapy and neoadjuvant therapy, like we'll talk about, is potentially an area in which other drugs and potentially combinations will be developed. So next, we will be discussing 3 abstracts evaluating the theme of combinations, and these abstracts are 9501, 9502, and 4010. Abstract 9501 is an evaluation of the combination of fianlimab and cemiplimab anti-LAG-3 and anti-PD-1, respectively, in advanced melanoma, specifically focusing on the post-PD-1 experience in this disease by Dr. Omid Hamid. 9502 is the updated 2-year survival results from RELATIVITY-047, which evaluated nivolumab and relatlimab against nivolumab alone in frontline metastatic melanoma. And Abstract 4010 are the results from the MORPHEUS platform study, specifically looking at tiragolumab and atezolizumab in patients with advanced unresectable HCC. But focusing on 9501 and 9502, Jason, what do you make of the combination of fianlimab and cemiplimab post-PD-1 setting? Dr. Jason Luke: I think the data look very intriguing for this second combination of PD-1 and LAG-3 combination. When nivolumab and relatlimab, the approved LAG-3 inhibitor, kind of burst on the scene a couple of years ago, it was somewhat to the surprise of a lot of people in the community who had really come to think that while PD-1 and CTLA-4 were core molecules for therapeutics and cancer, that we just weren't ever really going to see something else come along in checkpoint blockade. And so nivo and rela got approved. We'll talk about them again in a second. But the data now coming forward for another PD-1 LAG-3 combination, again with cemiplimab PD-1 and fianlimab LAG-3, looks very, very promising. So in Abstract 9501, they updated a phase 1 expansion cohort, phase 2 cohort looking at patients across the various different settings. And whereas in the treatment naive frontline metastatic setting they had previously described about a 63% response rate, they saw a similar level of response rate in patients who had previously gotten adjuvant anti-PD-1, had a period of time off treatment, and then were treated again. And that was reassuring because it suggested that this is still an active combination even with prior exposure to IO in the past. Now, the thing that I found to be the most interesting about this combination was whereas with nivo and rela, at least from the RELATIVITY-047 phase 3 trial, it looked like there was less benefit in some of the high-risk population cohorts, at least for this combination in early testing for cemi and fian; like we talk about it sometimes, we saw there was a high response rate even in patients with liver metastases and some other high-risk features. And so I think this combination looks quite potent, and I'm very excited to see what the data will look like. I think it's very unlikely we'll ever actually get a randomized trial of two PD-1 LAG-3 combinations against each other. But suffice it to say that the data we've seen so far for fianlimab LAG-3 with cemiplimab PD-1 looks very intriguing. It certainly justifies the frontline metastatic phase 3 and the adjuvant phase 3 trials that are already in planning or ongoing. Dr. Diwakar Davar: So one thing to consider is on the RELATIVITY-020 trial – the early trial that was led by Dr. Ascierto that really took a long time to read out – the response rate in patients with prior checkpoint inhibitor therapy was quite low. In fact, the data was quite surprising, as you'd mentioned that we had even seen this movement in the frontline setting because the response rate by BICR was only about 12%. So do you feel like the 2 LAG-3 inhibitors are fundamentally different? And if so, can you speculate as to why that might be? Again, with the caveat to the fact that these are very early data and we don't have enough information. And maybe we can also talk a little bit about the 2 pending trials that are ongoing in the advanced and adjuvant therapy landscapes perspective. Dr. Jason Luke: I think we don't have enough data yet to truly understand whether or not they're really different. The trials that have been run so far are so different that it's hard to compare things back and forth. You can notice that the dose, the milligram dosage of fianlimab in terms of anti-LAG-3 is quite a bit higher, like a log fold higher almost than with relatlimab. And so there's some question of whether or not just merely more drug-blocking LAG-3 might in fact be more efficacious relative to the dose that's approved for relatlimab in melanoma. But beyond that, I think the data hold up very well for this new combination, again noting all the caveats about cross-trial comparison to, say, it looks to be at least as potent, possibly more potent than the relatlimab combination. But again, I think probably we need to see the data from randomized trials and how that fits into the landscape when the trials actually read out because there's a lot of things going on in melanoma that are likely to change between now and then. Dr. Diwakar Davar: So just to draw people's attention, there are actually 2 ongoing pivotal phase 3 trials: fian plus cemi versus pembro in patients with advanced metastatic and locally advanced, previously untreated melanoma, as well as an adjuvant trial of the combination against pembrolizumab. Again, highly high-risk resected melanoma. These trials are ongoing. We don't have the results yet and we are looking forward to them. Now, 9502, a 2-year RELATIVITY-047 result presented by Dr. Hussein Tawbi. Dr. Jason Luke: So this is the study we were just alluding to before, the randomized phase 3 study of nivolumab versus nivolumab plus for relatlimab. To me, the most useful data sort of updating with this two-year survival follow-up is to show the maintenance of benefit between the 2 arms. And so, consistent with what we saw with nivolumab and ipilimumab, there seems to be a persistent delta between the arms for both progression-free and for overall survival out over that extended period of time, where we can see with that updated data now, at 2 years, that it's 52% of patients still alive on the relatlimab combo versus 42 with nivolumab. And it does seem like this is probably a higher-risk population of patients than participated in CheckMate-067. So it's a little bit difficult to compare the landmarks except to notice that that difference between the control and experimental groups is consistent over a long period of time and that there were no new safety signals either, and so that was also reassuring. To me, the most interesting nugget of data in the abstract, though, is to look at what happened to patients after they were on the first-line treatment. So one of the big questions in our field is really “If patients get nivolumab and relatlimab upfront, what should they get after that?” Should they then get nivo plus ipi, or vice versa? And I think we don't have an answer clearly to that question just yet. There was an important letter to the editor of the New England Journal now going on about a year ago by Alex Menzies and colleagues that suggested that the use of ipilimumab was attenuated, the utility of it, after a prior exposure to nivolumab plus relatlimab. They quoted a response rate on the order of only about 10% for patients who got an ipilimumab-containing regimen after initial LAG-3. In the data from Hussein Tawbi at ASCO, however, in a small number of patients, caveat, the response rate was more in sort of the low 20% range, 22% to 25%. And so that would be a much more meaningful and important sort of consideration. If we do have independent activity, then lining up sequential therapies and the toxicities associated with each will become increasingly important as we think about how to maximize these kinds of treatments for our patients, but important longer-term data to show that the benefit is holding up and it's safe, and some new insights into what to do after progression on one of these regimens. Dr. Diwakar Davar: So, pivoting slightly to combinations, we are going to be discussing a combination of TIGIT plus checkpoints. So tiragolumab is the FC-active TIGIT inhibitor from Regeneron-Roche and this is currently in multiple pivotal phase 3 trials, several of which have been negative, including SKYSCRAPER-01 in non-small cell lung cancer and SKYSCRAPER-03 in small cell lung cancer. The MORPHEUS platform trial essentially is a platform study evaluating multiple different combinations, in this case in liver cancer. And so we have a very interesting Abstract 4010, which is giving us an early readout of the evaluation of tiragolumab plus atezolizumab along with bevacizumab in unresectable, locally advanced or metastatic hepatocellular carcinoma giving us a result that is a little different from what we had seen from the prior negative results of TIGIT. So Jason, what do you make of these early results in the advanced HCC setting? Dr. Jason Luke: I think these are cautiously intriguing results to really highlight the point is the third checkpoint possibly being LAG-3, now a fourth checkpoint maybe with TIGIT, but with all the caveats that you talked about. In this study, the flow is that there's a continuously accruing control arm which in hepatocellular carcinoma is a combination of atezolizumab plus bevacizumab, and then other arms are added where you add in a third agent. In this case, it's the anti-TIGIT tiragolumab. And in an intriguing fashion, the response rate to the triplet was 42.5% compared to the doublet which was only 11%. So that's a pretty big difference in this population. Now, it wasn't the largest study, only 58 patients, but it was a randomized clinical trial. And so I think those data really make people kind of open their eyes again. It's worth a little bit of a caveat here that HCC is an unusual cancer in that what is deemed to be unresectable and therefore amendable to systemic therapy is a moving target and that requires multidisciplinary evaluation of patients. And so I think a larger number of patients would really be needed to fully understand this. But certainly, a fourfold increase in the benefit or in terms of response rate looks quite intriguing. I think the other piece of this is to be just cautious a little bit was when the initial data in non-small cell lung cancer in the CITYSCAPE study came forward, and they looked roughly sort of like this: There was more than a doubling in the PFS and the response rate, which is what triggered all of those phase 3 studies. So to me, this is enough to continue to be very interested in TIGIT as a therapeutic target. And there are many phase 3 trials already ongoing. And so I think, I'm cautiously optimistic that some of those actually will be positive and we could see more movement around TIGIT becoming a standard of care agent. Dr. Diwakar Davar: To your point about TIGIT being an interesting target, recent data looking at the neoadjuvant landscape in melanoma from Merck, with Merck, also FC-active TIGIT and also some data from authors looking at that TIGIT also presented in this case at ASCO specifically from the ARC-7 study. So very interesting target. Several pivotal trials have been announced. Do you know of any trials that are ongoing in the adjuvant setting in other diseases? Dr. Jason Luke: Well, as you alluded to, the vibostolimab data in melanoma for TIGIT in the neoadjuvant setting was interesting. And in fact, that has been enough to trigger a global, randomized phase 3 adjuvant study of pembrolizumab and vibostolimab versus pembrolizumab in melanoma. And that sort of takes us back to the beginning of our discussion here, building on the KEYNOTE-716 data. So, yes, TIGIT will be moving forward in the adjuvant space in melanoma and obviously at a static setting for several different tumor types with a PD-1 or PD-L1 backbone. Dr. Diwakar Davar: So now pivoting towards neoadjuvant therapy and non-small cell lung cancer. The standard of care in this setting was established by the CheckMate-816 trial that essentially established nivolumab plus chemotherapy in the setting of resectable non-small cell lung carcinoma path. Response rate in this setting is approximately 21%. And we have several studies that are essentially looking at novel combinations or in this case, different PD-1 inhibitors in this setting. So Abstract 8500 essentially looked at nivolumab plus relatlimab from a NEOpredict-Lung trial. Jason, do you want to tell us a little bit about this? Dr. Jason Luke: Yes, I think this is a very interesting study and that this is sort of our first peek at targeting LAG-3 in the context of lung cancer. So obviously we talked about LAG-3 for melanoma. Although the audience is probably aware that there have been neoadjuvant data for LAG-3 with relatlimab in melanoma that substantiated the phase 3 data for the metastatic setting. So one of the questions as we start to apply the LAG-3 in other diseases would be, “Do we see it hold up in both metastatic disease and in the neoadjuvant space?” But in this study, while there were no changes in the safety profile; it didn't impact on whether or not patients could have surgery. There really didn't look to be a big difference in this study between nivolumab and nivolumab plus relatlimab, with the major pathologic response as you alluded to right around 30% for both arms. Now, it wasn't really the biggest study, but that's certainly quite a bit in contrast with what we've seen in melanoma, where with a PD-1 inhibitor you get again 25%-30%, but with adding on LAG-3, that pushes you up closer to 60%. So I think these were very interesting data that probably put a little bit of an eyebrow raise to say, “Well, let's see what happens in the metastatic setting in lung cancer with the addition of relatlimab LAG-3 on top of a PD-1.” I think it might not be quite so straightforward as what we saw in melanoma, but we'll look forward to those results because those phase 3 trials in metastatic lung cancer should be maturing sometime in the next year or two. Dr. Diwakar Davar: The theme of neoadjuvant therapy non-small lung cancer, LBA100, which has again previously been discussed in an episode of this podcast by Dr. Jack West and Dr. Velcheti is KEYNOTE-671. And this is a study essentially that looked at pembrolizumab or placebo with platinum-based chemotherapy doublet and followed by resection. So again, a direct parallel to CheckMate-816. What do you make of the results that were reported by our colleagues in this setting, Jason? Dr. Jason Luke: So not to rehash this, because our colleagues in the lung cancer group have already discussed this at length and obviously they're experts in that disease, but we'll just note that there was a threefold increase in major pathologic response, which turned into a major advantage for event-free survival. And so I think this is at least the third PD-1, PD-L1 combination regimen for neoadjuvant lung cancer that looks very, very promising. It certainly, to me, seems like neoadjuvant consideration really should be the standard of care already moving forward. To me, what the big question that is left with is “Do we still need the adjuvant component after we give the neoadjuvant?” So, some of the trials are including neoadjuvant and adjuvant, some of them are only neoadjuvant. And I think that's going to be a really important question as we move into the future, both in terms of what is that contribution of the adjuvant component, and then again, going back to earlier in our discussion here, if there could be a major advantage to adding individualized neoantigen therapy, maybe it is important to have both. But I think that's one of the big questions we have to get teased out by the field over the next couple of years. Dr. Diwakar Davar: And finally pivoting towards cutaneous squamous cell carcinoma. We have 2 abstracts discussing perioperative therapy. So cutaneous squamous cell carcinoma is a high-TMB tumor. The median tumor mutation burden in this disease is threefold that of melanoma. This is a disease in which checkpoint inhibitor therapy is approved as a single agent both with pembrolizumab and cemiplimab on the basis of nonrandomized phase 2 trials. And increasingly, there has been early development in the perioperative setting. The first data in this space came from our colleague Dr. Gross at MD Anderson, who reported in a small, nonrandomized phase 2 trial of 20 patients, a path CR rate with two cycles of cemiplimab at approximately 50%. A larger multi-institutional phase 2 trial demonstrated that a longer duration of perioperative therapy of four cycles or 3 months of cemiplimab did not particularly improve the path response rates. The response rates were similar at approximately 50% as well. And what we have right now are 2 other trials. The first is the MATISSE trial, Abstract 9507 ,that evaluated nivolumab or nivolumab plus epilimumab in this disease. And the other one was the NEO-CESQ trial, or Abstract 9576, that evaluated neoadjuvant plus adjuvant therapy that's cemiplimab in the high-risk patient population. So we're starting with 9507. Jason, what do you make of the ipi and ipi-nivo data reported in this setting? Dr. Jason Luke: So I think this is a really interesting study because I think part of the intent is the clinical aspect of how you manage patients with cutaneous squamous cell carcinoma. For those that don't do cutaneous oncology, many of these patients have the development of lesions, which can be actually quite difficult to resect in a way that's not otherwise mutilating or cosmetically quite problematic. And that was part of the impetus for this trial where, again, they looked at either monotherapy PD-1 or a PD-1 plus CTLA-4, and they saw great success. As was predicted based on the other data that you alluded to, response rates are more than 50% near 60%, with actually a substantial number of patients on the trial actually refusing to have surgery after they received their neoadjuvant therapy because they were so certain that they had had a good outcome. So I think these data are quite reassuring in the context of all of this emerging data around cutaneous squamous cell carcinoma. We'll talk about this NEO-CESQ trial in just a second, but I think it really is emerging to be the standard of care very soon for the use of perioperative PD-1 for cutaneous squamous cell. Dr. Diwakar Davar: What do you feel about the dose and schedule of checkpoint inhibitor therapy used here? So the dose of ipilimumab used was ipi-1 and not ipi-3, and they waited 4 weeks. So when patients only got two cycles of Q2 weekly nivo, and one cycle of ipilimumab, do you think the responses would have been deeper if they'd waited longer? Dr. Jason Luke: I think it is possible that they might have been deeper, although I'm not totally sure about that. One of the other abstracts we're not directly mentioning here was a study in Merkel cell carcinoma which suggested that in fact, adding ipi and that also highly immuno-oncology-responsive tumor type did not add to the response rate. So I'm not totally sure about that. I think rather what would be most interesting here is sort of the sort of next generation of biomarker work. As part of their presentation, the MATISSE trial team showed gene expression profiling that really strongly identified which patients were going to do well on the trial. And I think that's probably eventually going to be how we need to think about this. There are patients in the neoadjuvant setting who are going to do really well with anti-PD-1 alone. And then for those who aren't, that's where we probably really need to think about do we need combos, how long to give the treatment, etc. And I think we're really only on the cusp in the beginning of this, which is exciting as we think about moving into the future. Dr. Diwakar Davar: Certainly, many combinations are being evaluated in this space and we are very excited for the data that it's about to hopefully come in the next couple of months to years. So the NEO-CESQ – it's quite a puzzle as to how to pronounce this acronym – and this evaluated cemiplimab in the high-risk setting. So it's worthwhile noting that Dr. Gross's first trial looked at high-risk stage 2, 3, and 4 disease. So the context of cutaneous squamous cell carcinoma that's node-positive disease and distant metastatic disease that is in one location or patients with node-positive disease invention. And his multi-institutional cemiplimab trial of four cycles evaluated included patients with stage 2, 3, and 4 disease. So here in a study just in stage 3 and 4 diseases, Dr. Ascierto reported the results of 2 cycles of cemiplimab and importantly, these patients had both the neoadjuvant and the adjuvant portion of cemiplimab. So, Jason, you mentioned earlier that one of the key aspects that we start thinking about neoadjuvant therapy is exactly how much do you need. Do you need both the pre-surgical therapy and the post-surgical therapy? Is the presurgical therapy enough? After all, neoadjuvant response equals cure. How much benefit are you getting from post-surgical portions? So what do you make of the results that they've seen here and what is the impact? How do you think we'll be disentangling the impact of the neoadjuvant and the adjuvant portion of the immunotherapy upon response and survival? Dr. Jason Luke: So just to leverage those comments, I think these data are reassuring because in this higher-risk group of patients, they saw excellent outcomes very similar to what Gross et al had previously reported. So that's good. To your question about how we are going to disentangle this adjuvant versus non-adjuvant question, there's a trial in melanoma called the NADINA trial which is ongoing now in which the use of the adjuvant therapy is actually risk-adapted. So after patients have an initial neoadjuvant treatment they're evaluated, and if they have had a pathologic complete response, they're actually going to stop that treatment and they're not going to give the neoadjuvant therapy. And so I think obviously it's a slightly different disease, but those kinds of data, I think, will be very meaningful to help us sort this out. And I'm not sure whether or not in cutaneous squamous we would need a different trial than in melanoma, although I think in a different tumor, maybe like, say, lung cancer, you probably would need a dedicated study to try to look at that because I think just the responsiveness to checkpoint blockade is going to vary quite a bit once you get outside of cutaneous oncology. But to summarize, reassuring that a similar pathologic response rate, and I think this question of adjuvant or nonadjuvant, I think that's the next question we've got to answer in the field. Dr. Diwakar Davar: We have now come to the end of our back-and-forth discussion on these very, very exciting abstracts. So Jason, thank you for highlighting these advances and for engaging in a robust discussion. Dr. Jason Luke: Thanks for having me. Dr. Diwakar Davar: And thank you to our listeners today for taking the time to listen to this podcast. You will find the links to the abstracts discussed today in the transcript of this episode. Finally, if you value the insights that you hear in the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcast. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers: Dr. Diwakar Davar @diwakardavar Dr. Jason Luke @jasonlukemd Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Diwakar Davar: Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences Consulting or Advisory Role: Instil Bio, Vedanta Biosciences Consulting or Advisory Role (Immediate family member): Shionogi Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences Research Funding (Inst.): Zucero Therapeutics Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy Dr. Jason Luke: Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical , Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof) Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio
In this episode of the Discomfort Practice, I'm excited to bring back a past guest: cultural consultant, performance producer and content creator Matisse Dupont. Matisse has spent the last decade facilitating interactive lectures and workshops on gender, sexuality, culture and identity. I enjoyed witnessing their evolution on social media - from being a TikTok-er famous for educating others about gender to showcasing their talents as a multi-disciplinary artist to founder of volunteer-run LGBTQIA+ community theatre company, The Queer Theatre Project. Matisse and I explore their life changes and public persona. In this episode, we focus on that and explore how Matisse has realigned and reconfigured who they are publicly to reflect where they are personally. They've recently navigated burnout as a content creator and dealt with a concussion, which stopped them using technology at the height of their TikTok fame. Matisse shares how time away from what they had become known for opened up space to re-assess and enjoy other aspects of themselves and their talents. We talk about how creating a mindfully artistic practice can open up space to explore - and how you don't ever have to stick to just one thing for the rest of your life. Matisse is an inspirational example of how you can completely change your life, realign with your purpose and not get caught up, staying in the constraints of what people already know you for (or your comfort zone). Settle yourself in for this refreshing and motivating episode. Enjoy! Key Points Discussed: Shaking up the Discomfort Practice, having Matisse introduce themselves. (1:30) The discomfort of changing trajectory: from having a successful career and being known as an expert in a field to then starting something completely new. (3:30) How dealing with a severe health issue affected Matisse as a successful content creator and gender educator. But how this time out, gave Matisse perspective. (5:50) How the social media algorithm was dictating the way to unauthenticity and interacting on social media in a combative way, as well as leading to burnout. (13:00) How Matisse's love of art came out of this period of discomfort in their life. (18:20) Meditative quality to painting as a creative outlet. (22:00) The transformative practice of not feeling stuck to one job or creative outlet, and being able to constantly evolve and transition. (31:00) Matisse's leaving message: “Change takes time, but not as much time as you think it'll take.” (40:00) Connect with Matisse: Matisse Website Matisse on Instagram Matisse on TikTok Matisse on Youtube Connect with Betsy: Betsy on Instagram Betsy on Twitter Betsy on Linkedin Rate, Review, Learn and Share Thanks for tuning into The Discomfort Practice. If you enjoyed this episode, please subscribe, follow, like, and/or drop us a five star and written review. Share this episode with others and help spread the word and grow our audience. Don't forget to tune into our other episodes and share your favourite ones on social media!
Voilà, c'est le moment « Matisse » que je vous ai annoncé mercredi. Anne-Laure va vous proposer de réaliser tranquillement, en quelques minutes, un dessin inspiré d'un tableau de Matisse. C'est un épisode de son podcast Créativité en jeu. J'ai moi-même réalisé ce dessin et je me suis bien amusée. Felicia est aussi fan du podcast d'Anne-Laure. Alors, on y va ? Je laisse la parole à Anne-Laure. www.onethinginafrenchday.com Lien vers le tableau de Matisse : https://bit.ly/3C9gZZh
À l'extrémité du jardin des Tuileries, côté place de la Concorde et Seine, se trouve le musée de l'Orangerie, consacré à la peinture impressionniste et postimpressionniste. C'est dans ce musée que vous pourrez voir Les Nymphéas de Claude Monet. Nous y étions, il y a quelques semaines, Anne-Laure et moi pour voir l'exposition consacrée au peintre Henri Matisse. Anne-Laure trouve toujours intéressant de connaître les différentes étapes de la création d'un tableau. Justement, dans l'exposition, il y avait dans une vitrine plusieurs séries de clichés pris lors de la réalisation de certains tableaux. www.onethinginafrenchday.com
Author John Baxter is back - this time discussing literature from the French Riviera. We tackle a lot, with a bigger focus on F Scott Fitzgerald and Marina Picasso (and her tell-all book). Book a walking tour with John and find his books here. Support The Earful Tower on Patreon and get the second half of this conversation. Find more from this French Riviera miniseries here. Things we mentioned (to help you with spelling and searching...) First ten mins John tasted bouillabaisse in Sète John's friend was in the town of Cabris The Villa Noailles in Hyères for the work of architect Robert Mallet-Stevens French Riviera and its Artists: Book by John Baxter Menton as the notorious place to die (tales of Yates, Beardsley, de Maupassant) 10mins to 20mins Cole Porter and his wife, their friends Gerald and Sara Murphy Hotel du Cap and the Fitzgeralds Le Train Bleu with gamblers and prostitutes (now a restaurant, saved by Georges André Malraux) Le Balzar restaurant in Paris Cafe de Flore, Le Coupole, Les Deux Magots restaurants in Paris Hotel Belles Rives where F Scott Fitzgerald stayed (in Juan-les-Pins, Antibes) - and he also stayed in the nearby town of Saint-Raphaël Tender is the Night: Dedicated "To Gerald and Sara—Many Fêtes" 20 mins onwards Sophia Antipolis where Super-Cannes is set (a book by J. G. Ballard) Zelda Fitzgerald's book: Save Me the Waltz Marina Picasso and and her tell-all book "Picasso, My Grandfather" La California - Picasso's summer shack/chateau/palace (featuring Matisse and Balthus too) Picasso's Portait of Olga in an Armchair Colombe D'Or in Saint Paul de Vence Carlton Hotel in Cannes Hotel Belles Rives
Dr. Diwakar Davar and Dr. Jason Luke discuss advances in melanoma, including targeted therapy and the addition of LAG-3 inhibitors to checkpoint therapy, as well as promising checkpoint inhibitors in cutaneous squamous cell carcinoma and Merkel cell carcinoma in advance of the 2023 ASCO Annual Meeting. TRANSCRIPT Dr. Diwakar Davar: Hello, and welcome to the ASCO Daily News Podcast. I'm your guest host, Dr. Diwakar Davar, and I'm an associate professor of medicine and the clinical director of the Melanoma and Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. I'm delighted to welcome my colleague and friend, Dr. Jason Luke. Dr. Luke is an associate professor of medicine and the director of the Cancer Immunotherapeutic Center at the University of Pittsburgh's Hillman Cancer Center. He is a very, very well-renowned physician-scientist who has done fundamental work in developmental therapeutics and also in melanoma. Today, we'll be discussing some key oral abstracts highlighting advances in immunotherapy in the cutaneous malignancy space that will be featured at the 2023 ASCO Annual Meeting. You will find our full disclosures in the transcript of this episode and the disclosures of all guests on the ASCO Daily News Podcast are available in our transcripts at asco.org/DNpod. Jason, thank you for coming on the podcast today. Dr. Jason Luke: Well, thanks so much for the opportunity. Dr. Diwakar Davar: So, we will go right ahead into the abstracts and the first one we thought we'd discuss is Abstract 9502, which is the RELATIVITY-047 study, specifically the 2-year results. This is the update. This has also been concurrently published at the New England Journal of Medicine Evidence online. And so in this publication and oral presentation, Hussein Tawbi, Georgina Long, and colleagues are talking about the nivo-rela data in the context of metastatic melanoma. So what is your take on this? What is your take on the data both presented and published and how would you contextualize this for the audience? Dr. Jason Luke: Right, so the RELATIVITY-047 study, as people will remember, randomized treatment-naive patients with metastatic melanoma to either receive nivolumab as standard treatment as a monotherapy or the combination of nivolumab and the anti-LAG-3 antibody relatlimab. And that study reported out a couple of years ago showing the improvement in progression-free survival as the primary endpoint. And at the time we saw that difference was approximately a 6-month absolute difference. And eventually, we saw there was an increase in the overall response rate also, again, approximately on the order of about a 10% change. What was interesting was that the overall survival initially was immature and that was an interesting follow-up point that we wanted to see. So I think what's important in seeing now this 2-year update of these data are the maintenance of the benefit for nivolumab plus relatlimab as compared to nivolumab alone across those measurements of progression-free survival and overall response rate. Interestingly, the overall survival in the clinical trial actually did not meet the pre-specified threshold for statistical significance. That being said, when you look at the data presented in the Kaplan-Meier plots and you think about the difference, it really does appear that there's a clinically meaningful difference between these 2 groups. And the statistical cut point only missed by about .01. And so this is one of those areas where one wonders whether or not subsequent therapies may have impacted on the overall survival calculation because obviously, patients in this trial had not received ipilimumab or a PD-1 CTLA-4 combination. So the take-home message from me in this data set was that the benefit of nivolumab and relatlimab was sustained over time and there was no suggestion of any late toxicities that might make us concerned. One advantage of this combination of nivolumab and relatlimab is the dramatically improved side effect profile relative to nivolumab and ipilimumab. So whereas immune-related adverse events that were serious, grade 3-4 is approximately 50% for nivolumab and ipilimumab, in the RELATIVITY-047 study, we see that the incidence of grade 3-4 toxicities for nivolumab and relatlimab is 17.2%, so that's less than half. So that's pretty attractive. And when we think about frontline management of patients, I think these data really support that nivolumab plus relatlimab is a reasonable consideration for some patients. And now I think the future question is really going to be, okay, well then who should get nivolumab and relatlimab versus who should still get nivolumab plus ipilimumab? Obviously, these data do not address that, and I think that that's probably the most important question for metastatic disease that's probably on the horizon. Dr. Diwakar Davar: Thank you, Jason, those are all fantastic points. It is interesting to note that as a result of the data, or really the lack thereof, the combination is actually not being launched in certain countries. So, for example, the German Health Authority, GBA, the Federal Joint Committee in Germany has decided against the acceptance of this agent because it does not accept event-free survival (EFS) as a patient-relevant endpoint. So it's interesting that we have an agent that is now going to be FDA-approved. It's already FDA-approved and available in the United States, but it will not be at least available in Germany and there may be other countries that decide favorably or unfavorably depending on how this OS data is viewed. So pivoting to another LAG-3 inhibitor in this case fianlimab, we're going to discuss Abstract 9501. So Abstract 9501 essentially is describing a phase II trial that evaluated the LAG-3 inhibitor, fianlimab, along with the anti-PD-1 inhibitor, cemiplimab from Regeneron. The data is slightly different from what we have seen with RELATIVITY-047, the Opdualag combination. So Jason, how would you contextualize the fian-cemi combination in advanced melanoma in the context of what we've seen with RELATIVITY-047? If you could help us with that, please. Dr. Jason Luke: Yeah, absolutely. So before we dive into this specific abstract, it's, like you mentioned, probably useful to just put all of this in context. Targeting LAG-3 as an immunomodulatory approach has actually been in clinic for a decade approximately. And so the relatlimab phase 1 started quite a long time ago. And there was data for nivolumab and relatlimab in PD-1 refractory patients with melanoma that showed not a tremendously obvious level of activity. And so it was thought there that the only place they would see that activity was to go to a frontline randomized phase 2 and then phase 3 trial, as we just discussed. In contrast to that, given all the data that had come forward about LAG-3 targeting with relatlimab, the group developing fianlimab took a different approach and rather treated a cohort of patients with treatment-naive melanoma to try to get an initial assessment right away of the activity as read out by overall response rate for this PD-1 plus LAG-3 combination, which is cemiplamab plus fianlimab. And these authors have previously presented data about this combination from cohorts of patients who are treatment-naive who received this combination and described approximately a 64% overall response rate. And that's an impressive number in the treatment-naive setting. There's sort of a tension there to sort of say, well, wait a minute, the response rate in this single-arm study is 64%, but in RELATIVITY-047, the response rate was lower for the LAG-3 combination and I think that's not a fair comparison. We have to realize this is a much smaller group of patients that has the potential to have been somewhat biased towards a better cohort just because of where and when they were recruited to participate in this trial. All the same, I think that number does look impressive and suggest that this combination is active in the frontline. Specific to this abstract, though, what the authors presented here was to update those previous data and then specifically also to focus on a cohort of patients who are allowed to have had previous treatment in the perioperative setting. So either neoadjuvant or adjuvant therapies. And in a subgroup of patients, they observed that even in the patients that had received adjuvant anti-PD-1 who went on to then progress later, they got actually a similar overall response rate at approximately 60% even in that group. And so I think that that seems like an exciting number as well. One would on first principles think that if patients got an adjuvant anti-PD-1, then a PD-1 LAG-3 combo could be less active. When and how the patients progressed or did not on that adjuvant therapy, however, I think makes a big difference. And given the relatively small sample size of patients that were included in this report, which is on the order of 20-ish patients who were in the previous PD-1 treated adjuvant cohort, I don't know that we can make super broad analyses trying to compare across the development programs. What I would take from this abstract, however, is that it does appear that this other PD-1 LAG-3 combination cemiplamab plus fianlimab is also very active and certainly deserves to be investigated in similar clinical trial contexts as the nivolumab plus relatlimab combination that we previously discussed. And while it's not specifically stated here, that is happening, there is a frontline phase 3 trial for this combination of fianlimab and cemiplamab as well as adjuvant considerations, also ongoing. Dr. Diwakar Davar: So, thank you. We've seen a lot of LAG-3 data this last 2 months, the phase 2/3a RELATIVITY-020 trial has just been published in the JCO, I encourage people to read that. And so that was the evaluation of nivolumab and relatlimabin the post-PD-1 patient population that Jason alluded to, where the response rate that was observed was 12%. So we've seen a lot of interesting data, a lot of interesting survival data, and now a new potential combination with LAG-3 with fianlimab and cemiplamab from Regeneron. So it'll be a very interesting next couple of years as we see whether or not this new combination, how it shakes up against the established nivu-rela combination, again, albeit with the limitations of cross-trial comparisons and also how it performs against cemiplamab in this ongoing, as you alluded to, ongoing global phase 3 trial. So, pivoting away from melanoma, now addressing the context of another cutaneous malignancy, a very high-risk one, Merkel cell carcinoma. So, Merkel cell carcinoma for those who are not necessarily treating a lot of this is a very rare and very aggressive cutaneous tumor. It's a neuroendocrine tumor of the skin. It's a cancer that's typically associated more than about 60% of the time with a cancer-causing virus, an oncogenic virus known as a Merkel Cell Polyomavirus. And in this setting, checkpoint inhibitor therapy has been approved for the last couple of years, initially with a PDL-1 inhibitor, avelumab, and then more recently with a PD-1 inhibitor, pembrolizumab. And, at this point in time, there are three FDA-approved agents that are checkpoint inhibitors that are available for the treatment of this disease. And CheckMate-358 was essentially a trial of nivolumab plus/minus ipilimumab in the setting of this Merkel cell carcinoma. So, Jason, what are your thoughts on how the addition of ipi did in this setting [in Abstract 9506]? Dr. Jason Luke: Yeah, so I think this is a really interesting abstract because there's a slightly more context even than what you alluded to there. This study is an open-label, multi-cohort, but single-arm investigation where one cohort of patients received nivolumab alone and the other cohort received ipilimumab. It needs to be buttressed by a previous publication in The Lancet last year by the group at the Moffitt Cancer Center who also did a prospective study looking at nivolumab and ipilimumab. In that previous study that the Moffit group did, they got a response rate of 100%. All patients responded to the combination of nivolumab and ipilimumab in their study and that was quite provocative, suggesting that while anti-PD-1 alone has about a 50% response rate, adding ipi in that scenario then took it to 100. So these data were very much of interest because this could be a confirmatory data set to suggest for this rare tumor that perhaps a combination regimen should be preferred. Of course, one has to remember that adding ipilimumab to anti-PD-1 substantially enhances the toxicity profile. And these patients tend to be elderly that develop this kind of cancer, Merkel cell carcinoma. So that's a rather important caveat. Just to get to the crux of what happened in this trial. As opposed to the previous Moffit trial, there actually did not appear to be a major increase in the benefit of adding ipilimumab, at least in this trial. Because again, in parallel cohorts, the NIVO monotherapy arm had a 60% response rate, which is roughly a little bit higher, but roughly in line with what we've seen previously. And the response rate to nivolumab plus ipilimumab was 58%. So, I mean basically the same. So, how can it be then, that we have this previous very high-profile publication that says 100% response? Now, we have a second publication that says adding ipi doesn't do anything - that's confusing, and I think it'll be really important to try to look at what were the differences between these two cohorts of patients. Did one of them have higher risk features, greater disease burden, et cetera? We don't really know that just yet, but trying to tease that out will be important. This data also emphasized, though, the complexity around the dosing of ipilimumab. And in melanoma, we never really figured out what the best dose of ipilimumab was to give either alone or even in combination with a PD-1. And we don't really have time to get into all of it right away here, but there are multiple studies in melanoma that would suggest that giving ipi on an every 3-week dosing schedule is superior to giving it on a 6-week dosing schedule. In this study, they did use the 6-week dosing schedule. So, whether or not that could have made a difference, I guess, is unknown. But I would notice that in the previous Moffitt trial, they also used that six-week dosing schedule. This one's a head-scratcher for why did these data not confirm a previous data set? But for the time being, I think this emphasizes that PD-1 monotherapy really is the standard approach that should be considered for patients with metastatic Merkel cell carcinoma. Dr. Diwakar Davar: That's great, Jason. And so, again, it's a very tough patient population. These are very rare patients. The Moffitt trial that Jason alluded to essentially was a trial that had in each arm, there were approximately 25 patients, of which 13, or between 11 to 13 patients were actually checkpoint inhibitor naive, wherein the dramatic 100% response rate was seen. And this is a trial where at least in this update, we've got about 25 patients in nivo monotherapy, I mean in 43 patients. And so, in a disease that is thought to be extraordinarily sensitive to checkpoint inhibitor immunotherapy because of the role of the virus and the high TMB that it's associated with, it is very interesting that the addition of an additional checkpoint inhibitor did not appear to improve outcomes. But as you alluded to multiple reasons, but we don't know how it's going to shake out. Next, Abstract 9507 and this is a very interesting trial known as the MATISSE trial. So, in the context of cutaneous squamous cell carcinoma, cutaneous squamous cell carcinoma is a relatively not uncommon cancer, primarily seen in older cancer patients, particularly a little bit more common in men. And in this setting, we've got checkpoint inhibitor therapy that is FDA-approved, at least two of which are FDA-approved right now, pembrolizumab and cemiplamab both were approved in the advanced cancer setting. And we do know that because of the extraordinarily high tumor mutation burden associated with cutaneous squamous cell carcinoma, checkpoint inhibitor therapy has got a very dramatic effect. Response rates are between 35% to 42% with pembrolizumab and 40% to 50% with cemiplamab, depending on whether or not one looks at the relapsed metastatic or the locally advanced patient populations. And interestingly, much like we've seen with melanoma, we have migrated the use of this therapy early in the lines of patients, particularly in the setting of perioperative therapy. So, Jason, how would you contextualize the results of the MATISSE trial in relation to the existing and known data from several of our colleagues regarding the role of what checkpoint inhibitor therapy is doing in terms of organ preservation? Dr. Jason Luke: Yeah, and I think this is an area of tremendous excitement. And as you were alluding to, the activity of anti-PD-1 really was transformative in this disease, which really can be a disfiguring and locally destructive disease. And with that activity for unresectable disease, last year, near the end of the year, there was a first report of a large neo-adjuvant clinical trial in cutaneous squamous which showed really outstanding results in terms of improving surgery and pathologic complete response using anti-PD-1 in that setting. And for this trial, this was a trial done in Europe; they took a similar tact of trying to think about giving anti-PD-1 or anti-PD-1 with anti-CTLA-4 with ipilimumab in that neoadjuvant period to see whether or not they could reduce the use of extensive surgery and/or radiation therapy. The short version is they were able to do that. And so they described 40% of patients with single-agent anti-PD-1 and 53% of patients who received a combination having major pathologic response to treatment. And this was so much so that 10 of the patients who had pathologic responses actually withdrew their consent to go on to have surgery because they decided that they had had such a good effect of the immunotherapy, they weren't willing to put themselves through what was going to be a very difficult surgery. And I think that speaks to the upside potential of these checkpoint immunotherapy approaches in certain settings, specifically here in cutaneous squamous cell carcinoma. Moreover, they describe clinical response in neoadjuvant setting as 50% for PD-1 monotherapy and 61% for the combination and I really think that this is really ready for prime time. With the study published in the New England Journal last year and these data now, I really think the field needs to start moving towards the use of perioperative anti-PD-1 with or without ipilimumab as a standard approach. And I think it's the case that even the NCCN and ASCO and various guideline societies are going to start acknowledging that this ought to be considered for most patients who are facing difficult surgical operations for continuous squamous cell carcinoma. Dr. Diwakar Davar: So, Jason, you bring up a fascinating point, which is the appearance of this in guidelines. So this is undoubtedly extraordinarily good data. It's confirmatory, the pathologic response rates in many ways paradoxically low. You'd expect something about 50% or so. But the reason it's low is because 10% of patients who actually benefited didn't undergo surgery. So really the degree of benefit is tremendous. It's about 50% to 60%. So the fascinating thing in the setting that we'd have is if one is going to try to get the drug FDA-approved, what we now have is the conventional setting in which one needs a definitive endpoint. And at least we know that pathological response rate is not a definitive endpoint in the context of melanoma or, for that matter, cutaneous squamous cell carcinoma. The only setting in which it is a regulatory endpoint is a non-small cell lung cancer or triple-negative breast cancer. But recently there's been some very exciting data from another PD-1 inhibitor called dostarlimab in a trial done by your former colleague Dr. Luis Diaz when he demonstrated a dramatic result of dostarlimab in the context of perioperative rectal cancer where it is micro-satellite high wherein the standard of care is typically very disfiguring abdominal perineal resection. So in the context of some of our listeners who might be thinking a little bit about how this pertains to regulatory approval, what are your thoughts about the paradigm of avoiding highly disfiguring surgery relating to what was seen in the rectal cancer discussion to what we're now seeing with perioperative therapy in the context of cutaneous squamous cell carcinoma? Dr. Jason Luke: I think it's a very important question. And the easy out for diseases that have a pattern of progression that is metastasis is to use event-free survival which can include both the pre-surgical and the post-surgical period in terms of looking for whether or not the cancer comes back. And that works for diseases potentially like lung cancer, like you said, maybe melanoma. In cutaneous squamous cell carcinoma, however, that's not probably going to work because this tends to be a locally invasive and less of a metastatic disease. So here then, we really need to have sort of organization across patient advocacy, dermatology, medical oncology to come up with what the most appropriate considerations are going to be for evaluating that long-term benefit because I think we need a tangible result that we can show the FDA. Everyone is really impressed by these results, and I think that next step is to craft this into a way that we have a measurable output that we can then go to them with and say bless this so that all of our patients can get this kind of treatment. Dr. Diwakar Davar: Really great discussion, Jason. And I think this is going to be an area of particular interest going forward, given both the number of trials that have been conducted in this space and also the role of the very interesting regulatory paradigm that has now been set initially at least with the rectal cancer that is microsatellite high and now potentially we will see with cutaneous squamous cell carcinoma. And so the final abstract that we have selected for you is Abstract 9511. And this is a trial that was conducted by a mutual colleague, Dr. Ryan Sullivan, and his colleagues. And it's essentially a trial of looking at targeted therapy with or without navitoclax in BRAF mutant melanoma patients. And part of the reason to highlight this, it's very interesting preclinical data supporting the addition of navitoclax, b but also a great example of an early trial that came through the CTEP portfolio. And so Jason, can you tell us about why this is exciting and how we might contextualize the addition of navitoclax to the targeted therapy backbone? Dr. Jason Luke: Sure. So listeners will be quite aware of targeting mutant BRAF as a therapeutic strategy across oncology that was really initially pioneered in melanoma with the development of vemurafenib as the first selective BRAF inhibitor. But the field, of course, moved eventually to BRAF and MEK combinations across essentially all settings. We know that dabrafenib and trametinib are now approved pan-cancer for anywhere we find a BRAF V600e mutation. In the context of melanoma, looking at mechanisms of resistance, we observed that they were quite heterogeneous with reactivation of elements of the mitogen-activated protein kinase pathway, the MAPK pathway. But also there were metabolic changes in the cancer cells themselves which could drive resistance and were downstream of some of those reactivation signaling points. So one of those is the induction of anti-apoptotic machinery in the cell. So activation of BCL-2 or Bcl-xL to try to save those melanoma cells when they were under stress by blockade with BRAF and MEK inhibitors. And that observation was made now about a decade ago or more. And that raised the possibility that repurposing a drug that was being used actually in the chemo malignancy space might be useful in augmenting targeted therapy. And that's where we come in with the navitoclax as a BH3-mimetic that can actually knock down those antiapoptotic proteins, BCL-2 Bcl-xL. And so that was the context for this initially phase I clinical trial of combining navitoclax with the dabrafenib and trametinib. And those data supported the safety of doing that and moved to this study, which was a randomized phase 2 study of that triplet regiment versus the dabrafenib and trametinib alone. And so this study started quite a long time ago, before the sort of initiation or widespread use of anti-PD-1 antibodies. And so it had to kind of undergo some various iterations throughout its course but eventually has now read out. And it had two primary endpoints, with one being focused on improving the complete response rate for targeted therapy because that's been associated with long-term outcomes as well as to look at the maximum tumor shrinkage of patients within this trial and of course to look at other endpoints like response rate, progression-free survival, et cetera. About half the patients who participated in the trial had prior immune checkpoint blockade and they were actually distributed evenly across the two arms. So we think that probably won't impact on the outcomes. And what was observed in the clinical trial was that in fact, the triplet did improve the complete response rate for targeted therapy. So navitoclax plus dabrafenib and trametinib had a complete response rate of 20% versus dabrafenib and trametinib alone being at 15%. Both of them had an overall response rate in the 80% range, with slightly higher for the triplet at 84% versus 80% for the double-edged standard therapy. There was also a suggestion that there may be a disproportionate benefit for the triplet actually in patients with smaller baseline tumors. And we know that the efficacy of targeted therapy is more pronounced in the lower-volume disease state. And so overall, when we look at this without really adding much toxicity, I think this is an intriguing place to look at further drug development. BRAF and MEK inhibition has been a backbone therapy in Melanoma for a long time, but we really haven't been able to move past it or augment it in any real way because of the heterogeneity of treatment resistance. And here, by going after metabolic changes, we perhaps might have the opportunity to enhance our targeted therapy somewhat further. And so we'll look forward to further results investigating this regimen in subsequent clinical trials. Dr. Diwakar Davar: Fantastic discussion, Jason. So these are all great insights. As you've heard, we've now discussed a couple of key abstracts covering major topics that will be presented, major themes of the malignancy space at ASCO 2023, including the addition of a lactate inhibitor to checkpoint in both a randomized large phase 3 trial and a smaller phase 2 trial, the context of targeted-therapy in melanoma making another forerun in the post-3c setting. And two very interesting studies I have looked at, checkpoint inhibitor therapy in the context of cutaneous squamous cell carcinoma and Merkel cell carcinoma, addressing themes that are of huge importance going forward, including the role of perioperative therapy in squam and the addition of a CTLA-4 inhibitor in Merkel. These oral abstracts are all going to be presented at the 2023 ASCO Annual Meeting. We look forward to seeing you there. So, thank you Jason for taking the time to join us and for highlighting these important advances in immunotherapy. And thank you to our listeners for your time today. You will find links to the abstracts discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcast. Thank you for your attention. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers: Dr. Diwakar Davar @diwakardavar Dr. Jason Luke @jasonlukemd Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Diwakar Davar: Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences Consulting or Advisory Role: Instil Bio, Vedanta Biosciences Consulting or Advisory Role (Immediate family member): Shionogi Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences Research Funding (Inst.): Zucero Therapeutics Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy Dr. Jason Luke: Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical , Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof) Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio
We asked ChatGPT: “Tell me about the future of Visual Art and AI.” ChatGPT response: Artificial intelligence (AI) has become an increasingly popular tool in the field of art, with artists and technologists exploring the potential of machine learning algorithms to generate and manipulate images, music, and other creative works. AI applications can assist visual artists in creating art, improving their workflow, and exploring new creative possibilities. We asked ChatGPT: “Tell me about DALL_E.” ChatGPT response: DALL-E is a state-of-the-art AI language model developed by OpenAI that can generate images from textual descriptions. The name “DALL-E” is a combination of the artist Salvador Dali and the Pixar character WALL-E. With DALL-E, users can input textual descriptions of objects, scenes, or even abstract concepts, and the AI will generate a corresponding image. We asked ChatGPT: “Send me quotes about artists from fictional characters in real movies.” ChatGPT response: – “Every artist has their own unique voice. It's our duty to let it out and let it be heard.” [A Star is Born, 2018] – “The purpose of art is to provoke, to challenge, and to make people feel something they've never felt before.” [Harry Potter and the Deathly Hallows – Part 2, 2011] – “I don't want to be just a painter; I want to be Van Gogh.” [The Goldfinch, 2019] – “Artists have to be selfish sometimes, right? Gotta do what you gotta do to create something special.” [We Are Your Friends, 2015] We'll ask Sandy Davies, Ursula Wong, S.A. Grant, Nicky Jurd, and Morgan O'Donnell for their take on The Future of Art and AI: What Would Dali, Rembrandt, Picasso, Van Gogh, Matisse and Pollock Say?